The positive opinion is based on results from the Phase 3 BRUIN CLL-313 and BRUIN CLL-314 trials, previously presented at the 2025 American Society of Hematology Annual Meeting and published in The Journal of Clinical Oncology
BRUIN CLL-313 is the first Phase 3 study to evaluate a non-covalent BTK inhibitor exclusively in patients with treatment-naïve CLL and BRUIN CLL-314 is the first Phase 3 CLL trial to compare non-covalent and covalent BTK inhibitors, as well as the first to compare any BTK inhibitors in the treatment-naïve setting
If granted marketing authorization, this would expand pirtobrutinib's indication as a treatment option for patients with CLL in the European Union across all lines of therapy
, /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jaypirca (pirtobrutinib), a non-covalent Bruton tyrosine kinase (BTK) inhibitor, for the treatment of adults with chronic lymphocytic leukemia (CLL) across all lines of therapy and regardless of prior BTK inhibitor treatment. Following this positive opinion, the application is now referred to the European Commission for final action. The European Commission's decision is expected in the next one to two months.
"Results from BRUIN CLL-313 and BRUIN CLL-314 provide compelling evidence that pirtobrutinib can make a meaningful difference for people living with CLL across multiple lines of therapy," said Paolo Ghia, M.D., professor, medical oncology, Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milano, Italy. "The strong efficacy and tolerability demonstrated in these trials underscores the clinical value pirtobrutinib may offer patients. This positive opinion from the CHMP is an exciting and significant milestone, bringing us closer to a future where pirtobrutinib is an option for more people with CLL across the European Union."
Results from BRUIN CLL-313 and BRUIN CLL-314 were presented at the American Society of Hematology (ASH) Annual Meeting and Exposition in December 2025 and published in The Journal of Clinical Oncology.
"Based on the strong results from the BRUIN CLL-313 and CLL-314 studies, we believe Jaypirca has the potential to serve as a meaningful new option for newly diagnosed patients and those who have not yet received a BTK inhibitor," said Jacob Van Naarden, executive vice president and president of Lilly Oncology. "Thanks to the impact of contemporary CLL treatments, many patients may receive fewer lines of therapy over their lifetime, making treatment choices in earlier lines profoundly important. This CHMP opinion represents a step toward an important global approval for Jaypirca in this indication and reflects our ambition to make Jaypirca available to every CLL patient who may benefit, at any line of therapy. Today, we are on the brink of making that a reality across the European Union as we await the European Commission's final decision."
Lilly has also submitted these results to the U.S. Food and Drug Administration (FDA) for approval for adult patients with CLL, with a decision expected in the second half of 2026.
About BRUIN CLL-313
BRUIN CLL-313 is a Phase 3, global, randomized, open-label study of pirtobrutinib versus chemoimmunotherapy (BR) in people with CLL/SLL without 17p deletions who have not been previously treated. The trial enrolled 282 patients who were randomized 1:1 to receive pirtobrutinib (200 mg orally, once daily) or BR per labeled doses. BR is a chemoimmunotherapy regimen used in the treatment of CLL. The primary endpoint is PFS as assessed by blinded IRC. Secondary endpoints include investigator and IRC assessed ORR, duration of response (DoR), and PFS, OS, time to next treatment (TTNT), safety and tolerability and patient-reported outcomes (PRO).
About BRUIN CLL-314
BRUIN CLL-314 is a Phase 3, randomized, open-label study of Jaypirca (pirtobrutinib) versus Imbruvica (ibrutinib) in patients with CLL/SLL who were either treatment-naïve, or who were previously treated and were BTK inhibitor-naïve. The trial enrolled 662 patients who were randomized 1:1 to receive pirtobrutinib (200 mg orally, once daily) or ibrutinib (420 mg orally, once daily). The primary endpoint is ORR as assessed by blinded IRC. Secondary endpoints include investigator and IRC-assessed PFS, duration of response (DoR) and event-free survival (EFS), and time to next treatment (TTNT), OS, safety and tolerability, and patient-reported outcomes (PRO).
About Jaypirca (pirtobrutinib)
Jaypirca (pirtobrutinib, formerly known as LOXO-305) (pronounced jay-pihr-kaa) is a highly selective (300 times more selective for BTK versus 98% of other kinases tested in preclinical studies), non-covalent inhibitor of the enzyme BTK.1 BTK is a validated molecular target found across numerous B-cell leukemias and lymphomas including mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL).2,3 Jaypirca is a U.S. FDA-approved oral prescription medicine, 100 mg or 50 mg tablets taken as a once-daily 200 mg dose with or without food until disease progression or unacceptable toxicity.
About Chronic Lymphocytic Leukemia (CLL)
CLL is a form of slow-growing non-Hodgkin lymphoma that develops from white blood cells known as lymphocytes.4,5 CLL is one of the most common types of leukemia in adults.6 There are roughly 100,000 new cases of CLL globally each year, and the overall incidence of CLL in Europe is approximately 4.92 cases per 100,000 persons per year.6,7 In CLL, the cancer cells are present in the blood.6
INDICATIONS FOR JAYPIRCA (pirtobrutinib) (in the United States)
Adult patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have previously been treated with a covalent BTK inhibitor. Adult patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor. This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical trial benefit in a confirmatory trial. IMPORTANT SAFETY INFORMATION FOR JAYPIRCA (pirtobrutinib)
Infections: Fatal and serious infections (including bacterial, viral, fungal) and opportunistic infections occurred in Jaypirca-treated patients. Across clinical trials, Grade ≥3 infections occurred (25%), most commonly pneumonia (20%); fatal infections (5%), sepsis (6%), and febrile neutropenia (3.8%) occurred. In patients with CLL/SLL, Grade ≥3 infections occurred (32%), with fatal infections occurring in 8%. Opportunistic infections included Pneumocystis jirovecii pneumonia and fungal infection. Consider prophylaxis, including vaccinations and antimicrobial prophylaxis, in patients at increased risk for infection, including opportunistic infections. Monitor for signs and symptoms, evaluate, and treat. Based on severity, reduce dose, temporarily withhold, or permanently discontinue Jaypirca.
Hemorrhage: Fatal and serious hemorrhage has occurred with Jaypirca. Across clinical trials, major hemorrhage (Grade ≥3 bleeding or any central nervous system bleeding) occurred (2.6%), including gastrointestinal hemorrhage; fatal hemorrhage occurred (0.3%). Bleeding of any grade, excluding bruising and petechiae, occurred (16%). Major hemorrhage occurred when taking Jaypirca with (2.0%) and without (0.6%) antithrombotic agents. Consider risks/benefits of co-administering antithrombotic agents with Jaypirca. Monitor for signs of bleeding. Based on severity, reduce dose, temporarily withhold, or permanently discontinue Jaypirca. Consider withholding Jaypirca 3-7 days pre- and post-surgery based on surgery type and bleeding risk.
Cytopenias: Jaypirca can cause cytopenias, including neutropenia, thrombocytopenia, and anemia. Across clinical trials, Grade 3 or 4 cytopenias, including decreased neutrophils (27%), decreased platelets (13%), and decreased hemoglobin (11%), developed. Grade 4 decreased neutrophils (15%) and Grade 4 decreased platelets (6%) developed. Monitor complete blood counts regularly. Based on severity, reduce dose, temporarily withhold, or permanently discontinue Jaypirca.
Cardiac Arrhythmias: Cardiac arrhythmias occurred in patients taking Jaypirca. Across clinical trials, atrial fibrillation or flutter were reported in 3.4% of Jaypirca treated patients, with Grade 3 or 4 atrial fibrillation or flutter in 1.6%. Other serious cardiac arrhythmias such as supraventricular tachycardia and cardiac arrest occurred (0.4%). Cardiac risk factors such as hypertension or previous arrhythmias may increase risk. Monitor and manage signs and symptoms of arrhythmias (e.g., palpitations, dizziness, syncope, dyspnea). Based on severity, reduce dose, temporarily withhold, or permanently discontinue Jaypirca.
Second Primary Malignancies: Across clinical trials, second primary malignancies, including non-skin carcinomas, developed in 9% of Jaypirca-treated patients, most frequently non-melanoma skin cancer (4.4%). Other second primary malignancies included solid tumors (including genitourinary and breast cancers) and melanoma. Advise patients to use sun protection and monitor for development of second primary malignancies.
Hepatotoxicity, Including Drug-Induced Liver Injury (DILI): Hepatotoxicity, including severe, life-threatening, and potentially fatal cases of DILI, has occurred in patients treated with BTK inhibitors, including Jaypirca. Evaluate bilirubin and transaminases at baseline and throughout Jaypirca treatment. For patients who develop abnormal liver tests after Jaypirca, monitor more frequently for liver test abnormalities and clinical signs and symptoms of hepatic toxicity. If DILI is suspected, withhold Jaypirca. If DILI is confirmed, discontinue Jaypirca.
Embryo-Fetal Toxicity: Jaypirca can cause fetal harm. Administration of pirtobrutinib to pregnant rats caused embryo-fetal toxicity, including embryo-fetal mortality and malformations at maternal exposures (AUC) approximately 3-times the recommended 200 mg/day dose. Advise pregnant women of fetal risk and females of reproductive potential to use effective contraception during treatment and for one week after last dose.
Adverse Reactions (ARs) in Patients Who Received Jaypirca
The most common (≥30%) ARs in the pooled safety population of patients with hematologic malignancies (n=704) were decreased neutrophil count (54%), decreased hemoglobin (43%), decreased leukocytes (32%), fatigue (31%), decreased platelets (31%), decreased lymphocyte count (31%), calcium decreased (30%).
Mantle Cell Lymphoma
Serious ARs occurred in 38% of patients, with pneumonia (14%), COVID-19 (4.7%), musculoskeletal pain (3.9%), hemorrhage (2.3%), pleural effusion (2.3%), and sepsis (2.3%) occurring in ≥2% of patients. Fatal ARs within 28 days of last dose occurred in 7% of patients, most commonly due to infections (4.7%), including COVID-19 (3.1% of all patients).
Dose Modifications and Discontinuations Due to ARs: Dose reductions in 4.7%, treatment interruption in 32%, and permanent discontinuation of Jaypirca in 9% of patients. Permanent discontinuation in >1% of patients included pneumonia.
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma from Single-Arm and Randomized Controlled Clinical Trials
Serious ARs occurred in 47-56% of patients across clinical trials. Serious ARs in ≥5% of patients in the single-arm trial were pneumonia (18%), COVID-19 (9%), sepsis (7%), febrile neutropenia (7%). Serious ARs in ≥3% of patients in the randomized controlled trial were pneumonia (21%), COVID-19 (5%), sepsis (3.4%). Fatal ARs within 28-30 days of last Jaypirca dose occurred in 8-11% of patients, most commonly due to infections (7-10%), including sepsis (5%), COVID-19 (2.7-5%), and pneumonia (3.4%).
Dose Modifications and Discontinuations Due to ARs: Dose reductions in 3.6-10%, treatment interruption in 42-51%, and permanent discontinuation of Jaypirca in 9-17% of patients. Permanent discontinuation in >1% of patients included second primary malignancy, pneumonia, COVID-19, neutropenia, sepsis, anemia, and cardiac arrythmias.
Strong CYP3A Inhibitors: Concomitant use increased pirtobrutinib systemic exposure, which may increase risk of Jaypirca ARs. Avoid using strong CYP3A inhibitors with Jaypirca. If concomitant use is unavoidable, reduce Jaypirca dose according to approved labeling.
Strong or Moderate CYP3A Inducers: Concomitant use decreased pirtobrutinib systemic exposure, which may reduce Jaypirca efficacy. Avoid using Jaypirca with strong or moderate CYP3A inducers. If concomitant use with moderate CYP3A inducers is unavoidable, increase Jaypirca dose according to approved labeling.
Sensitive CYP2C8, CYP2C19, CYP3A, P-gp, or BCRP Substrates: Use with Jaypirca increased their plasma concentrations, which may increase risk of ARs related to these substrates for drugs sensitive to minimal concentration changes. Follow recommendations for these sensitive substrates in their approved labeling.
Use in Specific Populations
Pregnancy and Lactation: Due to potential for Jaypirca to cause fetal harm, verify pregnancy status in females of reproductive potential prior to starting Jaypirca. Presence of pirtobrutinib in human milk is unknown. Advise women to use effective contraception and to not breastfeed while taking Jaypirca and for one week after last dose.
Geriatric Use: In the pooled safety population of patients with hematologic malignancies, patients aged ≥65 years experienced higher rates of Grade ≥3 ARs and serious ARs compared to patients <65 years of age.
Renal Impairment: Because severe renal impairment increases pirtobrutinib exposure, reduce Jaypirca dose in these patients according to approved labeling.
PT HCP ISI MCL_CLL Q42025
Please see Prescribing Information and Patient Information for Jaypirca.
About Lilly
Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news, or follow us on Facebook, Instagram, and LinkedIn. P-LLY
Trademarks and Trade Names
All trademarks or trade names referred to in this press release are the property of the company, or, to the extent trademarks or trade names belonging to other companies are referenced in this press release, the property of their respective owners. Solely for convenience, the trademarks and trade names in this press release are referred to without the ® and ™ symbols, but such references should not be construed as any indicator that the company or, to the extent applicable, their respective owners will not assert, to the fullest extent under applicable law, the company's or their rights thereto. We do not intend the use or display of other companies' trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about Jaypirca (pirtobrutinib), as a potential treatment for adults with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL), and the timeline for future readouts, presentations, and other milestones relating to Jaypirca and its clinical trials, and reflects Lilly's current beliefs and expectations. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of drug research, development, and commercialization. Among other things, there is no guarantee that planned or ongoing studies will be completed as planned, that future study results will be consistent with study results to date, that Jaypirca will receive additional regulatory approvals, or that Lilly will execute its strategy as expected. For further discussion of these and other risks and uncertainties that could cause actual results to differ from Lilly's expectations, see Lilly's Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release.
Endnotes & References
Mato AR, Shah NN, Jurczak W, et al. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study. Lancet. 2021;397(10277):892-901. doi:10.1016/S0140-6736(21)00224-5 Hanel W, Epperla N. Emerging therapies in mantle cell lymphoma. J Hematol Oncol. 2020;13(1):79. Published 2020 Jun 17. doi:10.1186/s13045-020-00914-1 Gu D, Tang H, Wu J, Li J, Miao Y. Targeting Bruton tyrosine kinase using non-covalent inhibitors in B cell malignancies. J Hematol Oncol. 2021;14(1):40. Published 2021 Mar 6. doi:10.1186/s13045-021-01049-7 Mukkamalla SKR, Taneja A, Malipeddi D, et al. Chronic Lymphocytic Leukemia. [Updated 2023 Feb 18]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan. Available from: https://www.ncbi.nlm.nih.gov/books/NBK470433/ The Leukemia and Lymphoma Society. NHL Subtypes. Access here: https://www.lls.org/lymphoma/non-hodgkin-lymphoma/nhl-subtypes. Accessed on October 25, 2023. Ou Y, Long Y, Ji L, et al. Trends in Disease Burden of Chronic Lymphocytic Leukemia at the Global, Regional, and National Levels From 1990 to 2019, and Projections Until 2030: A Population-Based Epidemiologic Study. Front Oncol. 2022;12:840616. Published 2022 Mar 10. doi:10.3389/fonc.2022.840616 Sant M, et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood. 2010. 116:3724–34. https://pubmed.ncbi.nlm.nih.gov/20664057/ Refer to: Kyle Owens; [email protected] (Media)
Michael Czapar; [email protected] (Investors)
In accordance with its policy in favour of employee shareholding, the Board of Directors of TotalEnergies SE (Paris:TTE) (LSE: TTE) (NYSE: TTE) decided, on Septe
Award continues program expansion capacity to meet rising domestic and international demand
, /PRNewswire/ -- Raytheon, an RTX (NYSE: RTX) business, was awarded a $1.1 billion contract from the U.S. Navy to produce AIM-9X Block II missiles to bolster U.S. military inventory and meet increased demand from allied nations.
Under the contract, Raytheon will produce AIM-9X missiles along with associated hardware and software for U.S. and Foreign Military Sales customers.
"Our teams have streamlined production, shortened lead times and ramped up deliveries of AIM-9X missiles to keep pace with growing demand," said Barbara Borgonovi, president of Naval Power at Raytheon. "This contract, along with our close partnership with the U.S. Navy, allows us to sustain that momentum and ensure U.S. and allied forces have this advanced, combat-proven capability they depend on in high threat environments."
AIM-9X is the most advanced infrared tracking, short-range air-to-air and surface-to-air missile, and it is combat-proven in multiple theaters around the world. The system is configured for easy installation on a wide range of modern aircraft and provides layered defense options with ground launched capabilities, including the National Advanced Surface to Air Missile System (NASAMS).
Trusted by the U.S. and more than 35 allied and partner nations, AIM-9X is a critical asset for ensuring strategic deterrence and operational advantage worldwide. To meet growing demand, Raytheon is increasing its production capacity to 2,500 missiles per year.
A majority of the work under this contract will take place in Tucson, Arizona. Raytheon is significantly expanding its engineering workforce in Tucson to support critical military programs across domains. Engineers with active security clearances and relevant technical experience ready to make a difference helping connect and protect our world can learn more by visiting our website.
About Raytheon
Raytheon, an RTX business, is a leading provider of defense solutions to help the U.S. government, our allies and partners defend their national sovereignty and ensure their security. For more than 100 years, Raytheon has developed new technologies and enhanced existing capabilities in integrated air and missile defense, smart weapons, missiles, advanced sensors and radars, interceptors, space-based systems, hypersonics and missile defense across land, air, sea and space.
About RTX
With more than 180,000 global employees, we push the limits of technology and science to redefine how we connect and protect our world. With industry-leading capabilities, we advance aviation, engineer integrated defense systems for operational success, and develop next-generation technology solutions and manufacturing to help global customers address their most critical challenges. The company, with 2025 sales of more than $88 billion, is headquartered in Arlington, Virginia.
For questions or to schedule an interview, please contact [email protected].
NEW YORK, June 26, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Intuit Inc. (NASDAQ:INTU) for potential securities fraud after its significant stock drop.
If you invested in Intuit, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/intuit-class-action-lawsuit.
Key Details of the Intuit ($INTU) Class Action Investigation:
Investigation Overview: Securities fraud regarding the company’s price positioning among DIY tax filers ahead of and during the 2026 tax seasonStock Decline: May 20, 2026 – 20% Stock DropAction: Contact BFA Law to discuss your rights Why is Intuit Being Investigated for Securities Fraud?
Intuit is a financial technology platform that serves consumers, small and mid-market businesses, and accountants through its offerings, which include TurboTax, Credit Karma, and QuickBooks.
During the relevant period, Intuit told investors that it had been preparing for the 2026 tax season “a couple of years ago” and that the company understood what worked in 2025, which was “being at the lowest price compared to alternatives.” Intuit also stated that the 2026 tax season was “off to a strong start” as the company was poised to deliver the “best price for our customers.”
In truth, it appears that the company was facing pressure among the most price-sensitive DIY tax filers and was not competitive on price in this segment.
Why did Intuit’s Stock Drop?
On May 20, 2026, Intuit released its fiscal Q3 2026 financial results, which included its 2026 tax season revenue. Intuit stated that it “did not have the overall tax season we expected” and that it “faced pressure among the most price-sensitive DIY filers.” Intuit stated that “[w]e [lost] on price,” and revealed that the company needed to evolve its business model by delivering the right lineup and price points to meet simple filers’ needs at the low end. Intuit also announced that TurboTax online paying units were expected to grow by only 2% as total IRS filers were expected to decline by approximately 30 basis points, representing the “most significant industry-wide contraction since the post-COVID tax season.”
This news caused the price of Intuit stock to decline $76.86 per share, or 20%, from a closing price of $383.93 per share on May 20, 2026, to $307.07 per share on May 21, 2026.
Click here for more information: https://www.bfalaw.com/cases/intuit-class-action-lawsuit.
What Can You Do?
If you invested in Intuit, you may have legal options and are encouraged to submit your information to the firm.
All representation is on a contingency fee basis; there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.
BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named “Elite Trial Lawyers” by the National Law Journal, “Litigation Stars” by Benchmark Litigation, among the top “500 Leading Plaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’ Bar” by Law360 and “SuperLawyers” by Thomson Reuters.
Most recently, The Legal 500 awarded BFA the most client satisfaction accolades of any plaintiff’s securities litigation law firm, with clients noting: “[t]here is no better service provider in the practice area,” “[t]he interest of the client is always front and center,” and “[t]here isn’t a better firm in this space.” One testimonial described the firm as “nimble and entrepreneurial,” with a “relentless focus on adding value for clients.”
Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.
For more information about BFA and its attorneys, please visit https://www.bfalaw.com.
Qualcomm outlined the acceleration of its diversification strategy at its 2026 Investor Day on June 24. In connection with the event, the semiconductor company announced updated long-term revenue targets.
Qualcomm now expects non-handset revenue of $40 billion by fiscal 2029, which includes more than $15 billion in data center revenue, more than $14 billion in IoT revenue and $10 billion in Automotive revenue.
Separately, Qualcomm expanded its partnership with Hugging Face to accelerate open, developer-focused artificial intelligence across devices and cloud infrastructure.
Stephanie Link, chief investment strategist, head of investment solutions and equity portfolio manager at Hightower Advisors, picked Rockwell Automation, Inc. (NYSE:ROK).
Rockwell Automation, on June 9, approved an additional $1 billion to repurchase shares of common stock, while the company’s board also declared a quarterly dividend of $1.38 per share.
Don’t forget to check out our premarket coverage here
Joseph M. Terranova, senior managing director for Virtus Investment Partners, recommended Merck & Co., Inc. (NYSE:MRK).
Merck, on June 22, said its investigational therapy tulisokibart achieved the primary endpoint in a Phase 3 study in moderately to severely active ulcerative colitis (UC), marking what the company described as the first positive Phase 3 induction results for an anti-TL1A biologic.
Joshua Brown, co-founder and CEO of Ritholtz Wealth Management, picked Simon Property Group, Inc. (NYSE:SPG).
On Thursday, Barclays analyst Richard Hightower maintained Simon Property Group with an Equal-Weight rating and raised the price target from $212 to $213.
Price Action Qualcomm gained 3.8% to close at $204.90 on Thursday. Rockwell Automation shares rose 4.1% to settle at $479.39 during the session. Merck shares gained 4% to close at $125.45 on Thursday. Simon Property shares 1.5% to settle at $225.49 during the session. Photo via Shutterstock
Market News and Data brought to you by Benzinga APIs
, /PRNewswire/ -- Mahoney Environmental, a leading used cooking oil (UCO) collection and recycling company, today recognized three food service operators whose quick reporting helped law enforcement arrest UCO thieves at two locations in Louisville, KY, and one in Fort Mill, SC.
Louisville, KY: Two Incidents, Two Arrests
Rob Carter and his brother Ken, owners of Ken Bowl and Dixie Bowl in Louisville, assisted in two separate UCO theft cases in early 2026. In February, Rob reported a theft at Ken Bowl to Louisville police; after a two-and-a-half-month investigation, the offenders were arrested. In March, a relative working on-site spotted an old ambulance backing up to the Mahoney UCO container. The vehicle was disabled and both the ambulance and the stolen UCO were seized. Each location will receive a check through Mahoney's Grease Theft Rewards Program.
Fort Mill, SC: Quick Action Catches Repeat Offender
On June 8, 2026, Brad Hartley, owner of Wing King Café in Fort Mill, SC, was alerted to a UCO theft from his Mahoney container and immediately contacted police. Officers located the vehicle and arrested the driver. Two full tanks of oil were stolen in the incident. The same vehicle had visited his location a month prior, leaving behind a container leak that cost Hartley nearly $2,000 to clean up. Mahoney Environmental will be recognizing Hartley with a check for his swift response and partnership in addressing the area's Grease Theft.
About Mahoney Environmental's Grease Theft Rewards Program
Mahoney Environmental's dedicated Theft Prevention Team works closely with law enforcement and customers to identify and prosecute UCO thieves.
All customers are eligible for cash rewards for information leading to arrest and conviction and the rewards vary between a misdemeanor or felony conviction. Rewards are granted per vehicle.
To report a theft or learn more, visit the Mahoney Environmental Grease Theft Rewards Program.
About Mahoney Environmental
Founded in 1953, Mahoney Environmental helps food service operators nationwide recycle used cooking oil, enabling nearly 100% material recovery at all facilities. In 2020, Neste (HEL: NESTE) acquired Mahoney Environmental, strengthening the global supply chain for sustainable aviation fuel and renewable diesel production.
Mahoney is a licensed EPA and ISCC Certified recycler committed to creating a safer planet for future generations.
Key Takeaways MKC says Flavor Solutions growth offset softer U.S. consumer trends, led by foodservice and CPG demand.MKC is refining pricing, packs, distribution and marketing to improve consumer trends by the third quarter.MKC topped earnings and revenue estimates, with gross margin up 270 basis points and operating income up 30%. McCormick & Company, Incorporated (MKC - Free Report) used its second-quarter call to make a clear case that Flavor Solutions is carrying the business, while management works to restore better volume trends in U.S. consumer spices.
Management reaffirmed its 2026 outlook, but much of the investor focus shifted to how quickly the company can fix pressure in the Americas consumer business and sustain the stronger industrial and foodservice backdrop.
MKC Finds Its Main Engine in Flavor SolutionsChairman, president and CEO Brendan Foley said the quarter’s most important feature was the acceleration in Flavor Solutions, where growth broadened across Flavors and Branded Foodservice customers. That strength more than offset softer consumer trends in the Americas.
Flavor Solutions' organic sales rose 3% in the quarter, with gains split nearly evenly between price and volume. In the Americas, the segment posted 4% organic growth, helped by large CPG customers, private label, high-growth innovators and stronger branded foodservice demand.
Foley also pointed to reformulation activity, beverage innovation and health-and-wellness projects as key demand drivers. In Q&A, he said those projects are commercializing faster than initially expected, which adds support to the second-half outlook for the segment.
McCormick Targets a Consumer Volume ResetThe softer spot remained Global Consumer, especially U.S. spices and seasonings. Foley said shifting demand patterns, wider price gaps and heavier competitive promotion hurt consumption in certain segments, even as the broader category still grew.
Management’s response is familiar but more targeted this time. Foley said McCormick is refining revenue growth management, adjusting price-pack architecture, expanding distribution and increasing value-focused marketing to improve trends by the third quarter and return to volume growth in the fourth.
That issue surfaced repeatedly in analyst questions. Barclays, BofA and TD Cowen all pressed management on whether the company can restore sustainable volume momentum. Foley’s answer was consistent: the playbook is similar to the one used two years ago, but execution is faster, more digital and aimed at narrower pockets of weakness.
MKC Uses Margin Gains to Fund ReinvestmentThe second quarter still showed strong financial leverage. Adjusted EPS came in at $0.80, which beat the Zacks Consensus Estimate of $0.69 by 15.9%. Revenues of $1.94 billion topped the Zacks Consensus Estimate of $1.90 billion by 2%. Gross margin expanded 270 basis points, and adjusted operating income rose 30%.
CFO Marcos Gabriel said the largest moving pieces behind margin expansion were accretion from McCormick de Mexico, productivity savings, surgical pricing and a tariff refund. The refund lowered the cost of goods sold by $28 million in the quarter and added about $0.07 to adjusted EPS.
Just as important, Gabriel said most of that tariff benefit is being used to absorb higher inflation tied to the Middle East conflict and other cost pressures. That framing mattered because management presented the quarter’s margin upside as a source of funding for reinvestment, not as a clean earnings windfall.
McCormick Pushes Ahead on Unilever FoodsFoley also spent time reinforcing confidence in the pending Unilever Foods combination. He said integration planning is advancing with a dedicated management office, 20 functional teams and more than 200 people working across both organizations.
Management reiterated the deal’s financial targets, including a 21% operating margin at close, mid- to high-single-digit adjusted EPS accretion within the first 12 months after closing and mid- to high-teens accretion by year three.
Analysts also tested the durability of that future margin profile. Foley and Gabriel argued the model does not assume unusually lean SG&A, and Gabriel said the path to 23% to 25% operating margins comes from layering synergies on top of the 21% starting point.
MKC Flags a Softer Third-Quarter Profit CadenceThe other area of scrutiny was the third quarter. Gabriel said adjusted operating income should grow in the high-single-digit to low-double-digit range, with continued gross margin expansion offset by heavier ERP spending, higher incentive compensation and a significant increase in brand marketing.
JPMorgan and BNP Paribas pushed on whether this reflected a change in expectations. Gabriel said it was more about SG&A phasing than a change in the company’s internal view, though he also acknowledged inflation is tracking toward the high end of the company’s mid-single-digit cost outlook.
Cash flow was one cleaner positive. First-half operating cash flow rose to $431 million from $161 million a year earlier, helped by profitability and working capital improvement, particularly in inventory days and payables. Leverage ended the quarter at about 2.9 times.
McCormick Leaves the Call on OffenseThe overall tone coming out of the call was constructive but not complacent. Management repeatedly pointed to the resilience of flavor categories, the breadth of the portfolio and the ability to redirect margin gains into brand support, innovation and distribution.
At the same time, executives did not underplay the strain on the U.S. consumer. The company’s message was that Flavor Solutions is performing ahead of plan, while consumer remediation is now the central execution task for the back half of fiscal 2026.
MKC’s Zacks Signals Still Lean CautiousMKC currently carries a Zacks Rank #4 (Sell), along with a Value Score of C, Growth Score of F, Momentum Score of C and VGM Score of D. Under the Zacks framework, weaker ranks reflect less favorable earnings estimate revision trends, while Style Scores help gauge value, growth and momentum characteristics.
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
That combination points to a more cautious near-term setup than the quarter’s headline beat alone would imply. The Zacks system places the greatest weight on estimate revisions, and the current rank can change as analysts update forecasts after the just-reported results.
Information in Investor’s Business Daily is for informational and educational purposes only and should not be construed as an offer, recommendation, solicitation, or rating to buy or sell securities. The information has been obtained from sources we believe to be reliable, but we make no guarantee as to its accuracy, timeliness, or suitability, including with respect to information that appears in closed captioning. Historical investment performances are no indication or guarantee of future success or performance. Authors/presenters may own the stocks they discuss. We make no representations or warranties regarding the advisability of investing in any particular securities or utilizing any specific investment strategies. Information is subject to change without notice. For information on use of our services, please see our Terms of Use.
*Real-time prices by Nasdaq Last Sale. Real-time quote and/or trade prices are not sourced from all markets. Ownership data provided by LSEG and Estimate data provided by FactSet.
IBD, IBD Digital, IBD Live, IBD Weekly, Investor's Business Daily, Leaderboard, MarketDiem, MarketSurge and other marks are trademarks owned by Investor's Business Daily, LLC.
DraftKings Predictions continues rapid growth, generating approximately $3.4 billion in annualized consumer volume within DraftKings' unified platform
BOSTON--(BUSINESS WIRE)--DraftKings Inc. (Nasdaq: DKNG) (“DraftKings” or the “Company”) today announced the launch of its proprietary prediction markets exchange, DKeX, with integration into the unified DraftKings: Sports & Casino app, further advancing the DraftKings Predictions experience. The launch positions the Company to innovate more rapidly through greater ownership over content depth, operating economics, and the end-to-end customer experience. DKeX marks the next phase in DraftKings’ prediction markets evolution, strengthening its ability to deliver differentiated sports experiences across the country alongside its leading sportsbook.
DKeX marks the next phase in DraftKings’ prediction markets evolution, strengthening its ability to deliver differentiated sports experiences across the country alongside its leading sportsbook.
Share "DraftKings is at its best when building innovative platforms that bring together technology, customer focus, and world-class execution to shape the future of sports engagement," said Jason Robins, Chief Executive Officer and Co-Founder of DraftKings. "The momentum we've seen on DraftKings Predictions in recent months reflects the significant progress we've made in delivering a more seamless and connected experience for sports fans. DKeX provides a vertically integrated foundation for DraftKings Predictions, strengthening our prediction markets content and capabilities, giving us greater control over the technology that powers those offerings, and enabling us to move faster as we continue enhancing our unified app."
The launch of DKeX comes as DraftKings Predictions continues rapid growth, with approximately $3.4 billion in annualized consumer volume and approximately $11.3 billion in annualized total trading volume for the week ended June 21. The Company expects continued growth throughout July, driven by ongoing enhancements to the platform, growing adoption of new event contracts and features such as combinations, and heightened interest surrounding the World Cup. Since launching in mid-May, more than 30% of customers have used combinations, which allow multiple individual contracts to be bundled into a single position, highlighting strong demand for a customizable, sports-first prediction markets experience.
“The launch of DKeX and its integration into our unified app is a major step forward in delivering a best-in-class customer experience in sports nationwide,” said Jeanine Hightower-Sellitto, DraftKings Senior Vice President and General Manager of Prediction Markets. “The pace of development across Predictions has been substantial, from expanding our event contract offerings to introducing key features like combos, which customers have quickly embraced. DKeX is the latest milestone in that progression and creates new opportunities to further expand the offering ahead of some of the biggest moments on the sports calendar.”
As part of DraftKings' all-in-one platform strategy, DraftKings Predictions continues to evolve within the unified app. The DraftKings Sports experience brings sports betting and prediction market trading together with sportsbook offerings and/or sports event contracts available based on customer location. Recent enhancements include Predictions Sports Combos, expanded pre-game and in-play stats, dedicated hubs for major events such as the World Cup, and an always-on Live tab that surfaces real-time sporting events, giving customers more opportunities to engage with key moments as they unfold. DraftKings also enhanced its Responsible Engagement tools through My Budget and Controls, an in-app destination for managing deposit limits and personalized activity alerts.
DraftKings Predictions has also expanded with additional event contract offerings, including MLB player and futures contracts, No Runs First Inning (NRFI) baseball, broader NBA and NHL selections, and international sports.
The DraftKings Sports experience is available nationally, including sports event contracts in 18 states. The Company applies its Responsible Engagement principles across its prediction markets offering, supporting informed participation through tools and resources, including the DraftKings Responsible Trading Center.
DKeX leverages the technology and CFTC license from DraftKings’ acquisition of Railbird Technologies.
To access prediction markets and more, customers can download the DraftKings: Sports & Casino app on iOS and Android.
About DraftKings
DraftKings Inc. is a digital sports and gaming company created to be the Ultimate Host and fuel the competitive spirit of sports fans with platforms that range across daily fantasy, regulated gaming, prediction markets and digital media. Headquartered in Boston and launched in 2012 by Jason Robins, Matt Kalish and Paul Liberman, DraftKings is the only U.S.-based vertically integrated sports betting operator. DraftKings’ mission is to make life more exciting by responsibly creating the world’s favorite real-money games, betting experiences and event contracts trading. DraftKings Sportsbook is live with mobile and/or retail sports betting operations pursuant to regulations in 30 states, Washington, D.C., Puerto Rico, and Ontario, Canada. The Company operates iGaming pursuant to regulations in five states and in Ontario, Canada under its DraftKings brand and pursuant to regulations in four states and in Ontario, Canada, under its Golden Nugget Online Gaming brand. DraftKings also owns Jackpocket, the leading digital lottery courier app in the United States. DraftKings’ daily fantasy sports platform is available in 44 states, Washington, D.C., and certain Canadian provinces. DraftKings' wholly-owned subsidiary GUS III LLC (d/b/a DraftKings Predictions) also operates DraftKings Predictions, offering federally regulated event contracts under CFTC oversight. DraftKings is both an official sports betting and daily fantasy partner of the NHL, PGA TOUR and WNBA, as well as an official daily fantasy partner of NASCAR, an official sports betting partner of the NBA and an authorized gaming operator of MLB. In addition, DraftKings owns and operates DraftKings Network, a multi-platform content ecosystem. DraftKings is committed to delivering responsible engagement tools and resources, while focusing on integrity and customer education.
Forward-Looking Statements
Certain statements made in this press release are “forward looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. When used in this press release, the words “estimates,” “projected,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “would,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside DraftKings’ control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. For a discussion of additional risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements, see DraftKings’ filings with the Securities and Exchange Commission. DraftKings does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Michael Dell is absolutely crushing it this year By You're currently following this author! Want to unfollow? Unsubscribe via the link in your email.
Michael Dell has become the world's fifth-richest person. SAUL LOEB / AFP via Getty Images Dell computers might not be flashy, but there's nothing dull about Michael Dell right now.
The founder and CEO of Dell Technologies is proving that tech fortunes don't have to be fleeting. Thirty years after he first became a billionaire, Dell is now the fifth-wealthiest person on the planet, according to the Bloomberg Billionaires Index.
The personal-computing pioneer has leapfrogged Warren Buffett, Jensen Huang, Steve Ballmer, Mark Zuckerberg, and Larry Ellison on the rich list this year.
His net worth has surged by around $77 billion since the start of January; only Elon Musk has gained more in that timeframe.
Dell's $216 billion net worth as of Thursday's close makes him one of six people with a $200 billion-plus fortune, along with Musk, Larry Page, Sergey Brin, Jeff Bezos, and Ellison.
His wealth surge has been fueled by a 225% jump in his company's stock price this year, which has raised its market value to $281 billion — more than Wells Fargo, Palantir, or IBM are worth.
Dell owns about 41% of the eponymous PC maker, which has tapped into the AI boom by selling a "full stack" of computing infrastructure to run AI models, including workstations, servers, storage, networking, and services.
Strong customer demand was evident in Dell's first-quarter earnings. Net revenue soared 88% from the same quarter last year to a record $44 billion, as net sales of AI-optimized servers rocketed 757% to over $16 billion. Operating income more than tripled to $3.7 billion.
Dell isn't the only tech titan to see his fortune balloon in 2026. Musk, the CEO of Tesla and SpaceX, has added more than $300 billion to his net worth and even briefly became a trillionaire after SpaceX went public earlier this month.
Page and Brin, the cofounders of Google-parent Alphabet and the world's second- and third-richest people, are up more than $23 billion each thanks to their company's climbing stock price.
Other centibillionaires have fared much worse. Ellison, Zuckerberg, Ballmer, and Arnault have seen roughly $40 billion wiped off each of their fortunes as investors have soured on some tech and luxury names.
Read next
Theron Mohamed You're currently following this author! Want to unfollow? Unsubscribe via the link in your email.
Theron Mohamed is a London-based correspondent on the Trending team at Business Insider. His coverage spans finance, investing, wealth, markets, and the economy.Theron joined BI in 2019 as a reporter at Markets Insider and rose to the rank of correspondent before moving to the Trending team in 2024. He previously covered tech, media, and telecom stocks for Investors Chronicle magazine and had a brief stint on the Financial Times' Data team. He interned at the Wall Street Journal in New York where he primarily wrote for Heard on the Street.Theron has freelanced for The Independent, The Telegraph, WIRED, and several smaller publications. He holds an undergraduate degree in geography from the London School of Economics, and a master's degree in journalism from Columbia University.Theron often covers Warren Buffett, Michael Burry, Jeremy Grantham and other top-flight investors. He also writes about the world's wealthiest people and shares financial advice from all manner of rich and successful people.Email Theron at [email protected] and follow him on X @theron_mohamed.Expertise
Corporate financeStocks and investingWealth and philanthropyBusiness historyUS economyWarren Buffett and Berkshire HathawayPopular articlesAl Pacino says he went from $50 million to broke, joining a long list of stars who've experienced money troublesAn oil tycoon sold his company for $26 billion this year — but died before the deal closedWarren Buffett drinks 5 cans of Coke a day — here's why he switched from Pepsi after nearly 50 yearsMeet the 16 people in the $100 billion club — who are jointly worth more than Amazon or Google'Big Short' investor Michael Burry kept quiet, piled into China tech, and won big with a stock bet in 2024Bill Gates' former assistant is worth $154 billion — and could soon be richer than the Microsoft cofounderHoward Schultz talked about Steve Jobs, trademarking the latte, and Starbucks' problems in a marathon interviewWarren Buffett just made a rare trip to Tokyo. Here's the story of a disastrous sushi dinner that made him swear off Japanese food forever.21 states where recession bells are ringing after unemployment jumpsWarren Buffett is building the Noah's Ark of rainy-day funds. Here's why he's stacked up more than $300 billion.The 'Shark Tank' star Kevin O'Leary warns couples not to combine finances: 'I don't care how in love you are'The Waltons are once again the world's wealthiest family, beating out Gulf royalty and fashion dynasties
Tech Wealth AI More Tech stocks Billionaires Warren Buffett Elon Musk Mark Zuckerberg
Applied Materials Inc (NASDAQ:AMAT) experienced a significant Power Inflow alert, a key bullish indicator that is closely tracked by traders who value order flow analytics, specifically institutional and retail order flow data.
Understanding the Power Inflow Signal
Order flow analytics analyze real-time buying and selling trends by examining the volume, timing, and order size across both retail and institutional traders. These insights offer a more detailed understanding of price behavior and market sentiment for a stock, allowing the trader or institution to make the most informed decision possible.
AMAT Intraday Performance
At the time of the Power Inflow, AMAT was priced at $612.34. Following the signal:
• Intraday High: $669.22 (+9.29%)
This article is for informational purposes only and does not constitute financial advice, investment recommendations, or a solicitation to buy or sell securities. The analysis is based on stock order flow data, but accuracy is not guaranteed. Investing involves risk, including possible loss of principal, and past performance is not indicative of future results. Please consult a licensed financial advisor before making any investment decisions.
Benzinga Disclaimer: This article is from an unpaid external contributor. It does not represent Benzinga’s reporting and has not been edited for content or accuracy.
Market News and Data brought to you by Benzinga APIs
Carvana NYSE: CVNA delivered a genuinely impressive Q1 2026 earnings report that included a record number of units sold.
Carvana Today
$66.22 -1.69 (-2.49%)
As of 06/25/2026 03:59 PM Eastern
52-Week Range$54.46▼
$97.38P/E Ratio40.28
Price Target$93.14
However, in the two months following the report, CVNA is down approximately 15% despite favorable analyst sentiment. That includes a 10% drop on June 17 in sympathy with cost commentary from CarMax NYSE: KMX, even though Carvana's own unit economics are moving in the opposite direction.
Get Carvana alerts:
After the company’s strong Q1 numbers, Carvana still has operational fuel left in the tank. For example, the company’s AI-driven reconditioning tools haven't been rolled out at most facilities, meaning further margin expansion is on the runway.
The company's new Stellantis NYSE: STLA hybrid hub model has also shown early traction. The Casa Grande franchise reportedly went from 30 to 50 units per month to more than 700 after Carvana took it over.
Why Is CVNA Under Pressure?With all these positive factors driving the stock's outlook, why is CVNA under pressure? Some may say the issue is one of valuation. At 41x forward earnings, Carvana is priced like a technology stock. But the company’s innovative, online-only model has been disruptive to a market that wasn’t known for innovation. And, although the company doesn’t have a long history of profitability, the 41x figure is a discount to its historic average.
The company also cited the likelihood of lower gross profit per unit (GPU) in the coming quarter for a variety of reasons, including the year-over-year comparison to last year’s tariff anniversary. But that’s likely to be a one-time event and wouldn’t explain a sell-off that is now over 20% in 2026.
Carvana Is More Sensitive to Financing ConditionsThe real impact on CVNA is likely coming from something outside of its control. Specifically, the near-term direction of U.S. monetary policy. The tone of Federal Reserve chair Kevin Warsh's statements on June 17 did not indicate that he means to move towards an accommodative stance anytime soon.
The CME FedWatch tool agrees. The odds of a rate cut for the rest of 2026 are not even given a percentage. This may not satisfy investors who want to sharpen their pencils and look for a mathematical reason to sell Carvana in the company’s financials. But before dismissing it, here’s something to consider.
For an auto retailer, interest rates matter because auto loan rates are among the stickiest in consumer credit. The average used car APR is well above 11%. Trade-ins increasingly carry negative equity. A consumer who barely qualifies at current rates gets squeezed harder if rates hold or rise
Something else to consider, Carvana's competitor CarMax recently delivered earnings and, despite beating estimates and growing penetration, saw net income drop nearly 12% to $185.6 million as it cut prices to defend volume. Its loan-loss reserve also climbed to 2.95% of loans, up from 2.78%, as the company leaned harder into Tier 2. This is a category of consumers with strong but not top-tier credit who usually qualify for rates that carry a cost premium.
The typical Carvana customer skews to a lower FICO score than CarMax and is more dependent on financing. When rates stay high, marginal buyers are the first to be disqualified, and those are disproportionately Carvana's customers. There's also a K-shaped wrinkle to consider. Upper-leg consumers are still spending, but they're prioritizing travel and experiences over big-ticket vehicle purchases.
That does give fundamental investors something to consider. Restrictive policy compresses growth multiples hardest. At a 41x forward multiple, Carvana needs growth to deliver.
If higher-for-longer rates take $1 of earnings per share (EPS) away from CarMax, it could take 10x off CVNA's multiple. That puts Carvana’s 5-for-1 split last quarter into a different light.
Analysts Remain Bullish, But Technicals Stay WeakInstitutional buying was down sharply in the last quarter, but since the company’s earnings report, analysts have been mostly bullish on CVNA. The Carvana analyst forecasts on MarketBeat show a consensus price target of $93.14 as of June 24, representing a significant gain for investors. However, investors may have to wait until after Carvana reports earnings next month to get a better picture of analyst sentiment.
The CVNA chart shows a stock that continues to be in a downtrend, with recent rallies failing to crack the 200-day simple moving average. A bigger concern for investors may be volume, which is down sharply. The MACD also remains below its signal line, with the histogram near zero. There’s simply no real conviction one way or the other, which amplifies short interest of around 7%, which in and of itself isn’t bearish.
The next potential catalyst comes with Carvana's Q2 earnings report scheduled for July 29. Until then, CVNA is likely to stay tethered to macro signals rather than its own execution. The numbers say the company’s business model is working. The question is whether the Federal Reserve cooperates before the multiple compresses further.
Should You Invest $1,000 in Carvana Right Now?Before you consider Carvana, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Carvana wasn't on the list.
While Carvana currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
For years, retail margin accounts with less than $25,000 in equity were limited to fewer than four day trades within any rolling five-business-day window. When customers exceeded this threshold, they were subject to a 90-day account freeze. Now, 25 years later, regulators have scrapped the pattern day trading rule.
Robinhood Markets' (HOOD 3.92%) trading platform has historically served users with significantly fewer assets than those of traditional brokers. Without these users hamstrung by old pattern-day-trading rules, is Robinhood stock a buy?
Today's Change
(
-3.92
%) $
-3.81
Current Price
$
93.38
How Robinhood stands to benefit from the removal of the pattern day trade rule The Securities and Exchange Commission (SEC) and the Financial Industry Regulatory Authority (FINRA) overhauled Rule 4210, abolishing the pattern day trader (PDT) rule. Regulators eliminated the $25,000 equity and trade-counting requirements and replaced them with a $2,000 standard Regulation T minimum and risk-based intraday margin system. As a result, millions of smaller retail traders can day trade without restriction.
Robinhood's trading platform caters heavily to millennial and Gen Z investors, and these accounts tend to have lower average balances than traditional brokerages, along with higher trading activity. As of 2024, the average Robinhood account balance was around $4,000, and roughly one-quarter of accounts had a balance below the $25,000 threshold.
Image source: Getty Images.
Because this rule has constrained a large portion of Robinhood's active user base, its removal would unlock more trading opportunities, potentially boosting the company's transaction-based revenues through payment for order flow (PFOF) and exchange rebates. It also incentivizes cash account holders to upgrade to margin accounts to avoid settlement delays, potentially boosting margin interest revenue and Robinhood Gold subscriptions.
Robinhood CEO Vlad Tenev noted that "Robinhood worked alongside regulators and industry partners to make this happen," and that "this is exactly what we built Robinhood for." The change, which went into effect on June 4, comes on the heels of Robinhood already seeing stellar growth in trading volume, with average daily equities trading volume jumping 84% year over year in May.
Robinhood has done a good job of growing its business through new offerings over the past several years, including futures and index options, prediction markets, stock tokens, and agentic trading. The company's customer and asset bases continue to grow, and the removal of the PDT rule could further boost its volumes.
If Robinhood gets a bigger-than-expected boost from increased trading volume, the stock could surge. That said, investors are already paying up for strong growth ahead, with Robinhood stock priced right around 46 times forward earnings.
Groupon (GRPN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
MORGES, Switzerland--(BUSINESS WIRE)---- $INCY--Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis.
NEW YORK--(BUSINESS WIRE)--WisdomTree today announced that it received a top honor at the 2026 InvestmentNews Awards, with WisdomTree named ETF Provider of the Year.
The S&P 500 Index (SPX) SPX-0.01% continues to be subject to large intraday volatility. The U.S. benchmark index is showing resistance at 7,460 (the top of the gap), in addition to the resistance at 7,530 and 7,600-7,620.
MONTVALE, N.J., June 26, 2026 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ: BCPC), a global specialty ingredient manufacturer for health and nutrition markets, announced they will participate in the CJS Securities 26th Annual New Ideas Summer Conference on July 9, 2026. Ted Harris, Chairman of the Board, President and Chief Executive Officer, Martin Bengtsson, Chief Financial Officer and Allison Baurichter, Senior Director Investor Relations will participate in the conference.
About Balchem Corporation
Balchem Corporation develops, manufactures and markets specialty ingredients that improve and enhance the health and well-being of life on the planet, providing state-of-the-art solutions and the finest quality products for a range of industries worldwide. The company reports three business segments: Human Nutrition & Health; Animal Nutrition & Health; and Specialty Products. The Human Nutrition & Health segment delivers customized food and beverage ingredient systems, as well as key nutrients into a variety of applications across the food, supplement and pharmaceutical industries. The Animal Nutrition & Health segment manufactures and supplies products to numerous animal health markets. Through Specialty Products, Balchem provides specialty-packaged chemicals for use in healthcare and other industries, and also provides chelated minerals to the micronutrient agricultural market.
NEW YORK, June 26, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into The Ensign Group, Inc. (NASDAQ:ENSG) for potential securities fraud after significant stock drops.
If you invested in Ensign, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/ensign-class-action-lawsuit.
Key Details of the Ensign ($ENSG) Class Action Investigation:
Investigation Overview: Securities fraud relating to Ensign’s misrepresentations about care quality at the company’s nursing facilities, as well as Ensign’s growth, margins, and regulatory complianceStock Declines: June 8, 2026 – 8.2% Stock Drop; June 10, 2027 – 3% Stock DropAction: Contact BFA Law to discuss your rights
Why is Ensign Being Investigated for Securities Fraud?
Ensign is a healthcare services company that operates skilled nursing, senior living, and rehabilitative care facilities through a network of affiliated providers. Ensign relies heavily on Medicare and Medicaid reimbursements, making government funding and regulatory compliance central to Ensign’s business model.
BFA is investigating whether Ensign misled investors about the quality of care at its facilities, as well as Ensign’s growth, margins, and regulatory compliance.
Why did Ensign’s Stock Drop?
On June 8, 2026, Hunterbrook Capital published a research report titled “Ensign: The Nursing Home Empire Built on Fatal Neglect” based on a five month investigation that alleged “Ensign’s profits can be traced to providing less care than its patients need – and less care than it is meant to provide based on the tax dollars it receives from the government.” According to Hunterbrook, Ensign padded its profit margin by understaffing its facilities while routing Medicare and Medicaid payments to affiliate entities owned or controlled by Ensign.
This news caused the price of Ensign stock to decline $13.88 per share, or 8.2%, from a closing price of $170.30 per share on June 5, 2026, to $156.42 per share on June 8, 2026.
On June 11, 2026, Muddy Waters Research published a research report titled “Ensign: Deceiving the Government at Estimated ~20% of Facilities” which alleged that Ensign “rents” required nursing-home administrator licenses from off-site administrators that do not actually oversee its facilities to create the appearance of regulatory compliance. According to Muddy Waters, genuine regulatory compliance would significantly reduce Ensign’s profitability.
On this news, the price of Ensign stock declined $4.52 per share, or 3%, from a closing price of $151.65 per share on June 10, 2026, to $147.13 per share on June 11, 2026.
Click here for more information: https://www.bfalaw.com/cases/ensign-class-action-lawsuit.
What Can You Do?
If you invested in Ensign, you may have legal options and are encouraged to submit your information to the firm.
All representation is on a contingency fee basis; there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.
BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named “Elite Trial Lawyers” by the National Law Journal, “Litigation Stars” by Benchmark Litigation, among the top “500 Leading Plaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’ Bar” by Law360 and “SuperLawyers” by Thomson Reuters.
Most recently, The Legal 500 awarded BFA the most client satisfaction accolades of any plaintiff’s securities litigation law firm, with clients noting: “[t]here is no better service provider in the practice area,” “[t]he interest of the client is always front and center,” and “[t]here isn’t a better firm in this space.” One testimonial described the firm as “nimble and entrepreneurial,” with a “relentless focus on adding value for clients.”
Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.
For more information about BFA and its attorneys, please visit https://www.bfalaw.com.
The Zacks Coal industry is facing multiple headwinds as the use of coal in U.S. thermal power plants continues to decline. Per the U.S. Energy Information Administration (“EIA”), in 2026, demand for coal is projected to decline as usage of renewable sources increases for electricity generation. In addition, given the ongoing energy transition, marked by utility operators systematically phasing out coal assets, coal demand is expected to drop in 2026.
Amid the ongoing drop in coal usage and production, investors can watch coal stocks like Core Natural Resources, Inc., Alliance Resource Partners and Ramaco Resources, which have high-quality met coal production volumes, are expected to gain during this challenging phase.
About the IndustryThe Zacks Coal industry comprises companies involved in the exploration and extraction of coal through both surface and underground mining methods. Coal remains an important energy resource due to its high energy content and widespread use in electricity generation, as well as in steel and cement production. According to the EIA, the United States possesses nearly 252 billion short tons of recoverable coal reserves, with about 58% suitable for underground mining.
At current production rates, these reserves are expected to support coal supply for decades. Coal production is highly concentrated, with five states accounting for nearly 70% of total U.S. output and 60% of surface-mined coal. Yet, rising renewable energy adoption and the ongoing retirement of coal-fired power plants are expected to reduce coal demand over time, creating long-term challenges for the industry.
3 Trends That Could Weigh on the Coal IndustryDrop in U.S. Coal Production and Usage: Per EIA’s projection, coal production in the United States is expected to be 518 million short tons (MMst) in 2026, down 2% from the 2025 volume, due to lower usage of coal in power generation and higher usage of renewable sources. Coal production is expected to drop further by 4% year over year in 2027 and total 497 MMst.
Per EIA, coal’s share of U.S. electricity generation is projected to decline 100 basis points annually in 2026 and 2027, reaching 16% and 15%, respectively. EIA expects coal exports to increase modestly in 2026, supported mainly by higher metallurgical coal exports as additional production capacity comes online. Coal exports can help coal producers offset challenges arising from weakening domestic coal demand by providing access to additional markets and revenue opportunities.
Despite Reliability, the Emission Policy to Hurt the Coal Industry: Coal remains a dependable energy source, capable of providing around-the-clock electricity from generation units. However, rising environmental concerns are leading to a steady decline in its use for power generation. The United States’ Sustainability Plan targets a transition to 100% carbon pollution-free electricity by 2030 and net-zero emissions by 2050.
This shift is being accelerated by the increasing adoption of natural gas and renewable energy sources like solar and wind. Natural gas has become more cost-efficient due to advancements in fracking technology, while renewables have gained traction thanks to falling production costs and supportive government initiatives.
According to the EIA, U.S. coal consumption is expected to decline year over year in 2026 and 2027. 2026 U.S coal consumption is expected to drop 7.4% and 3.8% year over year in 2026 and 2027, respectively. Without substantial investment in pollution-control technologies for coal-fired power plants, domestic coal usage is likely to keep falling due to the retirement of coal-fired capacity.
Competition From Cleaner Energy Sources: Coal-fired power generation continues to face growing competition from lower-cost and cleaner energy sources, including natural gas, solar and wind. Abundant natural gas supplies and declining renewable energy costs have made these alternatives increasingly attractive to power producers.
Utilities are steadily reshaping their generation portfolios by adding more cost-efficient and environmentally friendly resources to reduce operating costs and meet stricter emissions requirements. Meanwhile, utility-scale solar projects paired with battery storage are becoming increasingly competitive with coal on a cost basis and are capturing the majority of new power-generation capacity additions. As renewable energy adoption expands and natural gas prices remain favorable, this will result in a decline in thermal coal demand.
Zacks Industry Rank Highlights a Gloomy Industry OutlookThe Zacks Coal industry is an eight-stock group within the broader Zacks Oil and Energy sector. The industry currently carries a Zacks Industry Rank #191, which places it in the bottom 23% of 247 Zacks industries.
The group’s Zacks Industry Rank, which is the average of the Zacks Rank of all the member stocks, indicates lackluster performance in the near term. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than two to one.
The industry’s position in the bottom 23% of the Zacks-ranked industries is a result of the negative earnings outlook for the constituent companies in aggregate. Looking at the aggregate earnings estimate revisions, it appears that analysts have lost confidence in this group’s earnings growth potential. Since June 2025, the coal industry’s earnings estimates for 2026 have declined 53.3% to $1.65 per share.
Before we present a few coal stocks that you may want to keep track of, let’s take a look at the industry’s recent stock market performance and valuation.
Coal Industry Outperforms the S&P 500 and the SectorThe Zacks Coal industry has outperformed the Zacks Oil and Gas sector and the Zacks S&P 500 composite over the past year.
The stocks in the coal industry have gained 31.3% compared with the Zacks Oil-Energy sector’s rally of 28.1%. The Zacks S&P 500 composite has gained 24.3% in the same time frame.
Coal Industry's Current ValuationSince coal companies have a lot of debt on their balance sheet, it makes sense to value them based on the EV/EBITDA (Enterprise Value/ Earnings before Interest Tax Depreciation and Amortization) ratio.
The industry is currently trading at a trailing 12-month EV/EBITDA of 9.71X compared with the Zacks S&P 500 composite’s 18.23X and the sector’s 6.61X.
In the past five years, the coal industry has traded as high as 11.65X and as low as 1.82X, with the median being 4.34X.
3 Coal Stocks That Could Weather the Industry SlowdownCore Natural Resources: Canonsburg, PA- based company, along with its subsidiaries, produces, markets and exports both metallurgical and thermal coal domestically and globally. Core Natural Resources has restarted longwall mining at its Leer South mine. The company secured major contracts across its segments at favorable prices. CNR currently has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The Zacks Consensus Estimate for its 2026 and 2027 earnings per share indicates year-over-year growth of 157.05% and 213.53%, respectively. The consensus estimate for its 2026 and 2027 sales implies year-over-year growth of 5.7% and 1.65%, respectively.
Alliance Resource Partners L.P.: Tulsa, OK-based Alliance Resource Partners produces and sells coal to utilities and industrial users in the United States. The firm produces coal from several mining complexes operated by its subsidiaries. ARLP earns royalty income from coal produced by the mining complexes and royalty income from mineral interests it owns in different basins. The contract to acquire certain general partner and limited partner interests in AllDale Minerals III, LP and AllDale Minerals IV, LP for $206 million will boost ARLP’s royalty income.
The Zacks Consensus Estimate for its 2026 and 2027 sales has increased year-over-year by 1.62% and 3.86%, respectively. The current distribution yield is 9.9%. The firm currently has a Zacks Rank #3.
Ramaco Resources, Inc.: Lexington, KY-based Ramaco Resources is the developer of high-quality, low-cost metallurgical coal and poised to benefit from improving metallurgical coal demand. To meet the demand, the company has restarted the Laurel Fork Mine and is expanding operations at the Berwind Mine by adding a third mining section. The company expects full-year metallurgical coal production of 3.7-4.1 million tons and total sales volumes of 4.1-4.5 million tons.
The Zacks Consensus Estimate for its 2026 and 2027 sales indicates year-over-year growth of 16.86% and 13.33%, respectively. The consensus estimate for its 2026 and 2027 earnings per share implies year-over-year growth of 72.73% and 300%, respectively. Ramaco Resources currently has a Zacks Rank #3.
Why Haven't You Looked at Zacks' Top Stocks?Since 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year.
Today you can access their live picks without cost or obligation.
See Stocks Free >>
Join us on Facebook: https://www.facebook.com/ZacksInvestmentResearch/
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
, /PRNewswire/ -- Catalyst Bancorp, Inc. (Nasdaq: "CLST") ("Catalyst"), the parent company for Catalyst Bank (www.catalystbank.com), and Lakeside Bancshares, Inc. (OTC Markets: "LKSB") ("Lakeside"), the parent company for Lakeside Bank, announced today that Lakeside shareholders have approved the pending merger with Catalyst and all required regulatory approvals have been obtained with respect to the previously announced mergers.
The mergers are expected to close on or about July 14, 2026, subject to the satisfaction or waiver of closing conditions.
About Catalyst Bancorp, Inc.
Catalyst Bancorp, Inc. (Nasdaq: CLST) is a Louisiana corporation and registered bank holding company for Catalyst Bank, its wholly-owned subsidiary, with $288.5 million in assets at March 31, 2026. Catalyst Bank, formerly St. Landry Homestead Federal Savings Bank, has been in operation in the Acadiana region of south-central Louisiana since 1922. With a focus on fueling business and improving lives throughout the region, Catalyst Bank offers commercial and retail banking products through our six full-service branches located in Carencro, Eunice, Lafayette, Opelousas, and Port Barre. To learn more about Catalyst Bancorp and Catalyst Bank, visit www.catalystbank.com, or the website of the Securities and Exchange Commission, www.sec.gov.
About Lakeside
Lakeside Bancshares, Inc. is a Louisiana corporation and registered bank holding company for Lakeside Bank, its wholly-owned subsidiary. Lakeside Bank is a Louisiana banking corporation and began operations on July 10, 2010 as a full-service financial institution. In February 2018, Lakeside Bancshares, Inc. (OTC Markets: "LKSB") was formed for the purpose of becoming the holding company of Lakeside Bank by a stock exchange.
Forward-looking Statements
This news release contains, and the officers and directors of Catalyst and its subsidiary may from time to time make, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are typically identified by words or phrases such as "may," "will," "anticipate," "estimate," "expect," "project," "intend," "plan," "believe," "target," "forecast," and other words and terms of similar meaning. Forward-looking statements involve estimates, expectations, projections, goals, forecasts, assumptions, risks and uncertainties.
Catalyst cautions readers that any forward-looking statement is not a guarantee of future performance and that actual results could differ materially from those contained in the forward-looking statements. Such forward-looking statements include but are not limited to statements about the benefits of the proposed mergers involving Catalyst and Lakeside and their subsidiaries, including future financial and operating results; statements about Catalyst's plans, objectives, expectations and intentions; statements about the expected timing of completion of the proposed mergers; and other statements that are not historical facts. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include risks and uncertainties relating to: (i) the risk that a condition to closing may not be satisfied; (ii) the timing to consummate the proposed mergers; (iii) the risk that the businesses will not be integrated successfully; (iv) the risk that the cost savings and any other synergies from the proposed merger may not be fully realized or may take longer to realize than expected; (v) disruption from the proposed mergers making it more difficult to maintain relationships with customers, employees or vendors; (vi) the diversion of management time on issues related to the mergers; and (vii) other factors which Catalyst discusses or refers to in its reports (such as the Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K) and other subsequent filings with the SEC, which are available on Catalyst's website or at the SEC's website at www.sec.gov.
Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on any forward-looking statement as a prediction of future events. Any forward-looking statement speaks only as of the date on which it is made, and except as required by law, Catalyst expressly disclaims any obligation to update its forward-looking statements whether as a result of new information, future events or otherwise. All subsequent written and oral forward-looking statements concerning the proposed transaction or other matters attributable to Catalyst or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above.
For more information:
Catalyst Bancorp, Inc.
Joe Zanco, President and CEO
(337) 948-3033
Lakeside Bancshares, Inc.
Roy Raftery, President and CEO
(337) 474-3766
June 26, 2026 07:00 ET | Source: Axsome Therapeutics, Inc.
NEW YORK, June 26, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that the first patient has been dosed in the FOCUS-3 Phase 3 trial evaluating solriamfetol as a treatment for adolescents with attention deficit hyperactivity disorder (ADHD).
FOCUS-3 (Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol) is a Phase 3, randomized, double-blind, placebo-controlled, multicenter trial to assess the efficacy and safety of solriamfetol in adolescents aged 12 to less than 18 years with ADHD. Approximately 468 patients will be randomized in a 1:1:1 ratio to receive one of two doses of solriamfetol or placebo for 6 weeks. The primary endpoint will be the change from baseline to week 6 in the ADHD Rating Scale (ADHD-RS-5) total score.
About Attention Deficit Hyperactivity Disorder (ADHD)
Attention deficit hyperactivity disorder (ADHD) is a chronic neurobiological and developmental disorder characterized by a persistent pattern of inattention, hyperactivity, or impulsivity, that interferes with functioning or development.1 Impairments in cognition are apparent in attention, planning and problem solving, working memory, and behavioral inhibition.2,3 An estimated 15.5 million adults and 7 million children in the U.S. are affected by ADHD,4,5 with approximately two-thirds or more of children with ADHD continuing to experience symptoms into adulthood.6 The total annual societal excess cost associated with adult ADHD in the U.S. has been estimated at over $120 billion.7
About Solriamfetol
Solriamfetol is a dopamine and norepinephrine reuptake inhibitor (DNRI), TAAR1 agonist, and 5-HT1A agonist being developed for the treatment of attention deficit hyperactivity disorder (ADHD), major depressive disorder (MDD) with excessive daytime sleepiness (EDS), binge eating disorder (BED), and excessive sleepiness associated with shift work disorder (SWD).
About Axsome Therapeutics
Axsome Therapeutics is a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) conditions. We deliver scientific breakthroughs by identifying critical gaps in care and develop differentiated products with a focus on novel mechanisms of action that enable meaningful advancements in patient outcomes. Our industry-leading neuroscience portfolio includes FDA-approved treatments for major depressive disorder, agitation associated with dementia due to Alzheimer’s disease, excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea, and migraine, as well as multiple novel product candidates addressing a broad range of serious neurological and psychiatric conditions that impact over 150 million people in the United States. Together, we are on a mission to solve some of the brain’s biggest problems so patients and their loved ones can flourish. For more information, please visit us at www.axsome.com and follow us on LinkedIn and X.
Forward Looking Statements
Certain matters discussed in this press release are “forward-looking statements”. The Company may, in some cases, use terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. In particular, the Company’s statements regarding trends and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the commercial success of the Company’s SUNOSI®, AUVELITY®, and SYMBRAVO® products and the success of the Company’s efforts to obtain any additional indication(s) with respect to solriamfetol and/or AXS-05; the Company’s ability to maintain and expand payer coverage; the success, timing and cost of the Company’s ongoing clinical trials and anticipated clinical trials for the Company’s current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including the Company’s ability to fully fund the Company’s disclosed clinical trials, which assumes no material changes to the Company’s currently projected revenues or expenses), futility analyses and receipt of interim results, which are not necessarily indicative of the final results of the Company’s ongoing clinical trials, and/or data readouts, and the number or type of studies or nature of results necessary to support the filing of a new drug application (“NDA”) for any of the Company’s current product candidates; the Company’s ability to fund additional clinical trials to continue the advancement of the Company’s product candidates; the timing of and the Company’s ability to obtain and maintain U.S. Food and Drug Administration (“FDA”) or other regulatory authority approval of, or other action with respect to, the Company’s product candidates, including statements regarding the timing of any NDA submission; the Company’s ability to successfully defend its intellectual property or obtain the necessary licenses at a cost acceptable to the Company, if at all; the Company’s ability to successfully resolve any intellectual property litigation, and even if such disputes are settled, whether the applicable federal agencies will approve of such settlements; the successful implementation of the Company’s research and development programs and collaborations; the success of the Company’s license agreements; the acceptance by the market of the Company’s products and product candidates, if approved; the Company’s anticipated capital requirements, including the amount of capital required for the commercialization of SUNOSI, AUVELITY, and SYMBRAVO and for the Company’s commercial launch of its other product candidates, if approved, and the potential impact on the Company’s anticipated cash runway; the Company’s ability to convert sales to recognized revenue and maintain a favorable gross to net sales; unforeseen circumstances or other disruptions to normal business operations arising from or related to domestic political climate, geo-political conflicts or a global pandemic and other factors, including general economic conditions and regulatory developments, not within the Company’s control. The factors discussed herein could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders, 5 ed., Arlington, VA: American Psychiatric Publishing, 2013.Brown TE. ADD/ADHD and Impaired Executive Function in Clinical Practice. Curr Psychiatry Rep. 2008 Oct;10(5):407-11.Nestler E., Hyman S., and Malenka R. Molecular Neuropharmacology: A Foundation for Clinical Neuroscience, Second Edition, 2nd ed., New York: McGraw-Hill Professional, 2008.Facts About ADHD in Adults. CDC. 2024.Data and Statistics on ADHD. CDC. 2024.Sibley MH et al. Variable Patterns of Remission From ADHD in the Multimodal Treatment Study of ADHD. Am J Psychiatry. 2022 Feb;179(2):142-151.Schein J et al. Economic burden of attention-deficit/hyperactivity disorder among adults in the United States: a societal perspective. J Manag Care Spec Pharm. 2022 Feb;28(2):168-179.
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by.
SummaryExpro Group Holdings is rated Speculative Buy, driven by margin expansion, technological specialization, and disciplined capital allocation amid sector cyclicality.XPRO’s Drive25 initiative and recent acquisitions have boosted adjusted EBITDA margins from 14% in 2021 to 22% in 2025, supporting operational efficiency.Despite a strong balance sheet and ~$275M backlog, XPRO trades at a discount due to market concerns over cyclicality and execution risk.Potential 35% upside exists if XPRO executes Drive25, integrates acquisitions, and achieves sector-median EV/EBITDA multiples, but risks remain from project delays and integration. Sadagus/iStock via Getty Images
Investment Thesis Expro Group Holdings (XPRO) is a well-established oilfield services company. Its core focus is on technological specialization, such as well flow management, well intervention, well integrity, subsea well access, production optimization, and managed pressure drilling.
6 Followers
Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
Key Takeaways CMC beat Q3 earnings and revenue estimates despite outages, weather and scrap-cost pressure.North America Steel expects better Q4 prices, margins and volumes as outage impacts fade.Precast backlog hit a record, supporting CMC's maintained fiscal 2026 EBITDA outlook. Commercial Metals Company (CMC - Free Report) used its third-quarter fiscal 2026 call to argue that reported strength still understated the business. Management pointed to temporary outages, weather disruptions and scrap-cost pressure that held back an even better quarter.
The more important message for investors was forward-looking. Executives said those issues have started to reverse, while backlog, pricing and integration trends support a stronger fiscal fourth quarter.
CMC Says the Quarter Did Not Show Full PotentialCommercial Metals reported adjusted earnings per share of $1.73, which beat the Zacks Consensus Estimate of $1.60, delivering a surprise of 8.1%. Third-quarter revenues were $2.48 billion, which also surpassed the Zacks Consensus Estimate of $2.37 billion by 4.9%.
President and CEO Peter Matt said the quarter reflected solid execution against the company’s strategic plan, but he stressed that results were dampened by temporary issues rather than a change in underlying demand. He tied the longer-term story to structurally higher margins, lower earnings volatility and a broader construction solutions footprint.
That framing mattered because management was not pitching the quarter as a peak. Instead, it positioned third-quarter performance as a transition point, with improving steel margins, better operating reliability and acquired precast assets beginning to add meaningfully to the earnings mix.
Commercial Metals Sees a Rebound in North AmericaThe North America Steel Group remained the central talking point. Adjusted EBITDA in the segment rose 41% year over year to $253.5 million, but it slipped sequentially as planned maintenance outages at seven of 10 mills, poor weather, and a lag between rising scrap costs and price increases weighed on results.
In the Q&A, a Goldman Sachs analyst pressed management on the bridge to a better fourth quarter. CFO Paul Lawrence said outages cost about $20 million and volume-related effects from weather, inventory tightness and commercial discipline cost roughly another $10 million. He added that those issues should reverse in the current quarter.
Matt also sounded firm on pricing. He said the recently announced steel price increases are taking hold and that CMC is not chasing discounting in the market. The company expects higher realized prices and improved metal margins in the fourth quarter, supported by healthy demand and major project activity.
CMC’s Precast Bet Is Moving to Center StageCommercial Metals’ Construction Solutions Group delivered one of the clearest strategic signals on the call. Net sales nearly doubled year over year to $394.6 million, and adjusted EBITDA increased 138% to $97.4 million, helped by $175.7 million of revenues and $52.9 million of EBITDA from the recently acquired precast businesses.
Management acknowledged that precast volumes were light in the quarter because shipment timing slipped by about two weeks and wet weather in the Southeast delayed deliveries. Still, Matt said the backlog reached a record level, and project releases have started to normalize heading into the fiscal fourth quarter.
That explains why CMC maintained its fiscal 2026 precast EBITDA outlook of $165 million to $175 million despite the third-quarter shortfall. Management also reiterated that the acquisitions are on plan operationally and commercially, with early lead sharing and network benefits already emerging.
Commercial Metals Finds More Than One TailwindCMC’s other margin lever remains its Transform, Advance, Grow program. Matt said the initiative is tracking well ahead of its targeted $150 million run-rate annualized benefit for fiscal 2026, with most gains so far coming from operational improvements such as scrap optimization, yield and logistics.
He used the Q&A to highlight a second phase of opportunity in commercial excellence. That includes cutting pricing leakage, deploying better tools and using the broader steel and precast platform to get involved earlier on large projects where CMC can influence design and capture more value.
Europe added another support point. The Europe Steel Group posted adjusted EBITDA of $34.7 million, aided by a $20.4 million CO2 credit and better market conditions. Management said CBAM, tighter EU safeguards and improving pricing are creating a more constructive supply-demand setup there.
CMC Nears a Cash Flow Inflection PointCapital allocation also drew scrutiny. Net leverage adjusted for acquisitions ended the quarter at 2.1x, and management said it remains confident in reaching below 2x by mid-2027 or sooner. Liquidity stood near $1.8 billion.
Matt said 2x leverage is the threshold that would reopen both larger shareholder returns and new growth opportunities. At the same time, he made clear that CMC wants more progress in integrating the two precast acquisitions before considering another sizable deal.
Lawrence added that fiscal 2027 capital spending should drop sharply as the West Virginia micro mill nears completion, setting up a stronger free cash flow profile. Management does not expect more mill investments, with future organic spending aimed at smaller, higher-return projects.
Commercial Metals Leaves With an Assertive ToneThe clearest read-through from the call was management’s confidence in the near-term setup. CMC expects a meaningful sequential increase in fourth-quarter core EBITDA, including about a $40 million benefit in North America from the end of outage impacts and from better volume and margins, plus mid-teens EBITDA growth in Construction Solutions.
Analyst questions focused on supply additions in rebar, imports, precast execution and Europe. Matt’s answers were notably direct, especially on market discipline, where he said CMC will prioritize value over volume and use trade remedies to defend the domestic market.
Taken together, management presented a company leaning into a more diversified earnings model. The tone was not built around a single quarter’s beat, but around improving margins, more stable end markets and a portfolio that management believes can generate stronger cash and lower volatility over time.
Zacks Signals Still Call for BalanceCMC carries a Zacks Rank #3 (Hold), alongside a Value Score of B, Growth Score of A, Momentum Score of A and VGM Score of A. In Zacks terms, the strongest combinations generally pair a Zacks Rank #1 (Strong Buy) or 2 (Buy) with Style Scores of A or B, while a Zacks Rank #3 can still be held when the score profile remains favorable. You can see the complete list of today’s Zacks #1 Rank stocks here.
The current mix points to attractive style characteristics across value, growth and momentum, but the Zacks Rank remains the primary signal in the framework. That rank can change as earnings estimate revisions move after the quarter, so the post-report revision trend remains the key factor to watch.
Cyprium Metals Ltd (ASX:CYM, OTCQB:CYPMF) has appointed experienced mining engineer and resources executive Christofer Catania as chief technical officer as the company advances the phased restart of the Nifty Copper Complex in Western Australia.
Catania joins Cyprium as work at Nifty shifts from construction and refurbishment toward practical completion, commissioning and operational readiness for the Phase 1 Copper Cathode Restart.
He brings extensive international experience across multiple commodities, including copper, with a background in project studies, operational delivery and technical leadership.
Technical appointment supports restart plans Catania was most recently senior vice president, global resources, at Worley, where he led technical, operational and strategic resources initiatives across several jurisdictions.
He was previously CEO of technical advisory firm MEC Mining and chief engineer for KAZ Minerals, an open pit copper producer of cathode and concentrate.
Catania is also a director of Emesent, a technology company that provides mobile LiDAR mapping solutions.
His technical expertise and industry experience will support the company’s next phase of growth, particularly as Nifty moves toward operations.
Nifty restart gathers pace Cyprium’s Phase 1 Copper Cathode Restart has advanced significantly, with work underway across acid storage, ponds, heap leach, solvent extraction, electrowinning, solution handling, filtration, firewater and electrical systems.
A key milestone was the commissioning of a new acid storage and distribution terminal, which allowed sulphuric acid deliveries to restart in late May.
This marked the first acid delivered to the site since the solvent extraction and electrowinning plant closed in 2006.
Cyprium executive chair Matt Fifield said Catania was already contributing to the company’s restart plans.
“Chris is creating immediate impact already,” Fifield said.
“As the competent person on our 2024 Nifty PFS and lead engineer on our Heap Leach restart plans, Chris is well familiar with the Cyprium team and our plans for the Nifty Copper Complex.
“Having him in-house has allowed us to accelerate all phases of planning, enhance our internal and external reporting and communications, and strengthen our technical foundation as we move into operations and continue to build Australia’s next great copper company.”
Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) has raised A$4 million to support commercial licensing activity, clinical trials and regulatory-enabling work for its synthetic anti-infective pipeline.
The placement, priced at A$0.40 per share, comprises 10.0 million new fully paid ordinary shares and was supported by new and existing institutional, sophisticated and professional investors.
Recce will also launch a share purchase plan (SPP) to allow eligible shareholders to subscribe for up to A$30,000 worth of new shares on the same terms as the placement, targeting up to an additional A$4 million before costs for a prospective total of $8 million..
Funds directed to licensing and clinical milestones The money from the placement and SPP will be used to strengthen Recce’s balance sheet for commercial licensing with a leading Middle Eastern pharmaceutical company, including initiatives to support a potential commercial agreement.
The company has allocated A$3.2 million to this area, alongside A$2 million for clinical trials targeting significant unmet medical needs.
This includes completion of a Phase 3 diabetic foot infections (DFI) registrational topical clinical trial in Indonesia, a Phase 3 DFI registrational topical clinical trial in Australia for the US Food and Drug Administration, and continuation of the US Department of War Burn Wound Program.
A further A$2 million will be used for activities enabling Investigational New Drug applications to the FDA and Indonesia’s BPOM, while A$800,000 will support general working capital and offer costs.
Following the offer, Recce expects pro forma cash liquidity before offer costs of about A$29.5 million, including anticipated additional funding from an estimated A$7.5 million R&D rebate and A$10 million in non-dilutive capital through an R&D advance.
Shareholder participation and option structure Participants in the placement and SPP will receive 1 free-attaching unlisted option for every two new shares issued.
The attaching options will have an exercise price of A$0.60 and expire on June 30, 2027. If exercised, holders will receive 1 fully paid ordinary share and 2 free unlisted piggyback options for each attaching option exercised.
The piggyback options will have an exercise price of A$1.00 and expire on June 30, 2028.
Recce said the offer of the attaching options and piggyback options would be made under a prospectus to facilitate secondary trading of shares issued on exercise, subject to ASX confirmation that the structure complies with Listing Rules.
“Exciting time” for Recce
Recce CEO James Graham said the capital raising came as the company progressed commercial and clinical milestones.
“The capital raising comes at an exciting time for the Recce business, having recently signed a non-binding term sheet with a leading Middle Eastern Pharmaceuticals Company and ahead of interim data readouts in Indonesia which is a positive step towards the potential commercialisation of R327G,” Graham said.
Anti-infective pipeline Recce is developing a new class of synthetic anti-infectives designed to address antibiotic-resistant infections.
Its pipeline includes RECCE® 327 as an intravenous and topical therapy for serious and potentially life-threatening bacterial infections, RECCE® 435 as an oral therapy for bacterial infections and RECCE® 529 for viral infections.
Recce's anti-infectives use multi-layered mechanisms of action intended to overcome resistance pathways used by bacteria and viruses.
Lululemon shareholders have elected three management-backed directors, including former Levi Strauss chief Chip Bergh, cementing the settlement of a bruising proxy battle with its founder and paving the way for the incoming CEO to focus on reviving the athleisure brand.
Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today:
ATI Inc. (ATI - Free Report) : This specialty materials and complex components company has seen the Zacks Consensus Estimate for its current year earnings increasing 5.5% over the last 60 days.
Harmonic Inc. (HLIT - Free Report) : This company which provides video delivery software, products, system solutions, and services has seen the Zacks Consensus Estimate for its current year earnings increasing 14% over the last 60 days.
LyondellBasell Industries N.V. (LYB - Free Report) : This chemical company has seen the Zacks Consensus Estimate for its current year earnings increasing 60.5% over the last 60 days.
Localiza Rent a Car (LZRFY - Free Report) : This car rental business from Brazil has seen the Zacks Consensus Estimate for its current year earnings increasing 13.3% over the last 60 days.
HCI Group, Inc. (HCI - Free Report) : This property, casulty insurance, information technology and real estate company has seen the Zacks Consensus Estimate for its current year earnings increasing 7.1% over the last 60 days.
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
HOUSTON and LONDON, June 26, 2026 (GLOBE NEWSWIRE) -- Baker Hughes (NASDAQ: BKR) will announce the results of the second quarter ending June 30, 2026, via press release at 5 p.m. Eastern Time (4 p.m. Central Time) on Sunday, July 26, 2026. A webcast to discuss the results will be held Monday, July 27, 2026, at 9:30 a.m. Eastern Time (8:30 a.m. Central Time).
To access the webcast, listeners should visit the Baker Hughes website at: investors.bakerhughes.com. An archived version will be available on the website following the webcast.
About Baker Hughes
Baker Hughes (NASDAQ: BKR) is an energy technology company that provides solutions to energy and industrial customers worldwide. Built on a century of experience and conducting business in over 120 countries, our innovative technologies and services are taking energy forward – making it safer, cleaner and more efficient for people and the planet. Visit us at bakerhughes.com.
NEW YORK, June 26, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against AeroVironment, Inc. (NASDAQ:AVAV) and certain of the Company’s senior executives for securities fraud after its significant stock drop resulting from potential violations of the federal securities laws.
If you invested in AeroVironment, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/aerovironment-class-action-lawsuit.
Key Details of the AeroVironment ($AVAV) Class Action:
Lead Plaintiff Deadline: July 27, 2026Alleged Misconduct: Securities fraud relating to AeroVironment’s contract to provide the U.S. Space Force’s SCAR program with its BADGER phased array antenna systemsLargest Alleged Stock Drop: March 2, 2026 – 17% Stock DropCourt: U.S. District Court for the Eastern District of VirginiaAction: Contact BFA Law to discuss your rights
Investors have until July 27, 2026 to ask the Court to be appointed to lead the case. The complaint asserts securities fraud claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in AeroVironment securities. The class action is pending in the U.S. District Court for the Eastern District of Virginia. It is captioned Norrell v. AeroVironment, et al., No. 26-cv-01429.
Why is AeroVironment Being Sued for Securities Fraud?
In May 2025, AeroVironment acquired BlueHalo, LLC, a defense technology firm specializing in advanced engineering. Three years earlier, BlueHalo had been awarded a $1.4 billion contract to deliver its BADGER phased array antenna systems to support the U.S. Space Force’s SCAR program.
According to the complaint, during the relevant period, AeroVironment consistently touted its SCAR contract and indicated it represented a “tremendous growth opportunity,” that AeroVironment’s work pursuant to the contract was “very much on track,” that the customer was “asking for more [BADGER systems],” and that the Company stood “ready to build more.”
As alleged, in truth, AeroVironment faced a significant likelihood of competition for the SCAR program and overstated its goodwill from its BlueHalo acquisition.
BFA Law is also investigating AeroVironment’s June 22, 2026, announcement that the financial statements in its quarterly report for the three and nine months ended January 31, 2026 “require restatement and should no longer be relied upon.”
Why did AeroVironment’s Stock Drop?
On January 20, 2026, AeroVironment announced that the U.S. government issued a stop work order on the Company’s agreement to deliver BADGER systems to the SCAR program, upon mutual agreement with the Company. This news caused the price of AeroVironment common stock to decline $61.97 per share, or 15.77%, from $392.86 per share on January 16, 2026, to $330.89 per share on January 20, 2026.
On March 2, 2026, Space News reported that the U.S. Space Force was reopening the SCAR program to suppliers other than AeroVironment and “are going to move into a new acquisition strategy for SCAR” which would “likely take the form of other companies building versions or variants of SCAR.” On this news, AeroVironment’s common stock dropped $43.93 per share, or 17.42%, from $284.24 per share at open on March 2, 2026, to a close of $208.32 per share.
Then, on March 10, 2026, AeroVironment announced its Q3 financial results reporting an operating loss of $179.0 million, compared to an operating loss of $3.1 million for the same period in fiscal year 2025. The company also announced the impact of a $151.3 million goodwill impairment in the AeroVironment’s space division after the stop work order tied to the Space Force’s SCAR program. This news caused the price of AeroVironment common stock to drop $13.84 per share, or 6.24%, from $221.57 per share on March 10, 2026, to $207.73 per share on March 11, 2026.
Click here for more information: https://www.bfalaw.com/cases/aerovironment-class-action-lawsuit.
What Can You Do?
If you invested in AeroVironment, you may have legal options and are encouraged to submit your information to the firm.
All representation is on a contingency fee basis; there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.
BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named “Elite Trial Lawyers” by the National Law Journal, “Litigation Stars” by Benchmark Litigation, among the top “500 Leading Plaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’ Bar” by Law360 and “SuperLawyers” by Thomson Reuters.
Most recently, The Legal 500 awarded BFA the most client satisfaction accolades of any plaintiff’s securities litigation law firm, with clients noting: “[t]here is no better service provider in the practice area,” “[t]he interest of the client is always front and center,” and “[t]here isn’t a better firm in this space.” One testimonial described the firm as “nimble and entrepreneurial,” with a “relentless focus on adding value for clients.”
Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.
For more information about BFA and its attorneys, please visit https://www.bfalaw.com.
This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.00% per year. These returns cover a period from January 1, 1988 through May 4, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
For Immediate ReleaseChicago, IL – June 26, 2026 – Today, Zacks Equity Research Lithia Motors (LAD - Free Report) and Sonic Automotive (SAH - Free Report) .
The Zacks Auto Retail and Wholesale industry enters the second half of 2026 navigating a complex landscape. New-vehicle demand has demonstrated notable resilience, supported by stable monthly sales volumes and broadening credit access, even as macro headwinds persist. However, sustained inflationary pressures, elevated vehicle prices and high borrowing costs continue to erode consumer purchasing power, disproportionately impacting mainstream and entry-level buyers. With full-year sales forecast at 15.8 million units— below 2025 levels— the industry faces pressure on volumes and margins.
Despite this backdrop, a few retailers like Lithia Motors and Sonic Automotive are better positioned to weather the cycle, backed by strategic acquisitions, ongoing digitization efforts and shareholder-friendly capital allocation.
About the IndustryThe auto retail and wholesale industry plays a key role in how cars, trucks and auto parts reach consumers. Companies in this space operate through dealership networks and retail chains, selling both new and used vehicles, offering repair and maintenance services, and facilitating customer financing. As a consumer-driven industry, its performance is closely tied to broader economic conditions — disposable income levels, interest rates, and consumer confidence all directly influence vehicle purchase decisions. The industry has also undergone meaningful structural change in recent years, with dealers increasingly investing in digital tools and e-commerce capabilities, a shift that continues to reshape how vehicles are bought and sold.
Key Investing ThemesResilient Demand and Stabilizing Sales Pace: Despite a volatile start to 2026 driven by weather disruptions, policy shifts and the Middle East energy shock, new-vehicle demand has proven surprisingly durable. Per Cox Automotive, the SAAR has held near 16.1 million for four consecutive months, including June, reflecting the underlying strength of consumer commitment to vehicle purchases. Strong equity markets and accumulated household wealth are also providing meaningful support, helping insulate demand despite elevated fuel prices and broader macro uncertainty.
Broadening Credit Access Supporting a Wider Buyer Pool: Per Cox Automotive, while average new vehicle loan rates remain elevated, it is a result of a broader mix of consumers now accessing financing, including lower credit tiers that were previously shut out of the market. Lenders have been expanding approval rates, extending loan terms, financing negative equity, and narrowing yield spreads, collectively widening the pool of eligible buyers. This broadening of credit access, even within a high-rate environment, should continue to support transaction volumes that might otherwise have deteriorated more sharply given current affordability pressures.
Eroding Consumer Purchasing Power: A sustained erosion of household purchasing power remains a key structural headwind for auto retail going into the second half of 2026. Per Cox Automotive, consumer price inflation has compounded at nearly 5% annually over the last five years, and personal expenditure growth continues to outpace income growth.
The average consumer's budget is under meaningful pressure. Energy costs remain a persistent drag, and unless inflation trends materially improve, discretionary spending on big-ticket purchases like vehicles will continue to face resistance— particularly in mainstream and entry-level segments where financing dependency is highest and budget sensitivity is most acute.
Elevated Vehicle Prices and High Borrowing Costs Suppressing Volume: Average transaction prices for new vehicles sit at approximately $49,220 — nearly 9% above where they would be had pre-COVID price growth trends continued. Layered on top of that, average new auto loan rates stand at 9.6%, having risen sharply from approximately 6.5% a decade ago. Cox Automotive's Vehicle Affordability Index highlights rising income requirements to purchase a new vehicle, with price-sensitive compact and subcompact segment buyers increasingly trading down to used vehicles or exiting the market entirely.
Year-Over-Year Volume Decline Pressuring Revenue Comps: Full-year new-vehicle sales are forecast at 15.8 million units, a 2.9% decline from 2025. While some of this softness reflects last year's outperformance rather than a fundamental demand collapse, negative unit comps create meaningful headwinds for revenue growth and operating leverage across the industry. In a business with high fixed costs at the dealership level, even modest volume declines can compress margins and pressure earnings comparisons through the remainder of 2026.
Zacks Industry Rank Isn't EncouragingThe Zacks Auto Retail & Wholesale industry is part of the broader Zacks Auto-Tires-Trucks sector. The industry currently carries a Zacks Industry Rank #167, which places it in the bottom 32% of nearly 245 Zacks industries.
The group’s Zacks Industry Rank, which is the average of the Zacks Rank of all the member stocks, indicates weak near-term prospects. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
The industry’s position in the bottom 50% of the Zacks-ranked industries is a result of a negative earnings outlook for the constituent companies in aggregate. Looking at the aggregate earnings estimate revisions, it appears that analysts are losing confidence about this group’s earnings growth potential. Over the past year, the industry's earnings estimate for 2026 has declined roughly 8%.
We will present a couple of stocks that you might consider adding to your watchlist. But before that, let’s discuss the industry’s recent stock market performance and valuation picture.
Industry Lags Sector and S&P 500The Zacks Auto Retail & Whole Sales industry has lost roughly 4%, underperforming the Zacks S&P 500 composite as well as the Auto, Tires and Truck sector over the past year, which grew 26% and 16%, respectively.
Industry's Current ValuationSince automotive companies are debt-laden, it makes sense to value them based on the enterprise value/earnings before interest, tax, depreciation and amortization (EV/EBITDA) ratio.
On the basis of the trailing 12-month EV/EBITDA, the industry is currently trading at 9.1X compared with the S&P 500’s 18.23X and the sector’s trailing 12-month EV/EBITDA of 26.76X.
Over the past five years, the industry has traded as high as 9.45X, as low as 4.78X and at a median of 7.21X.
2 Stocks Worth ConsideringSonichas grown into one of the most diversified franchised auto retailers in the United States. The 2021 acquisition of RFJ Auto Partners cemented its position among the top five U.S. dealership groups, while its more recent acquisition of four Jaguar and Land Rover dealerships in California made it the largest U.S. retailer of those premium brands— adding meaningful exposure to the higher-end segment that has shown relative resilience in 2026.
Beyond traditional auto retail, Sonic is expanding into powersports through its Sonic Powersports unit, now operating 20 rooftops across 46 franchises following its Harley-Davidson dealership acquisitions, positioning it among the top five U.S. powersports groups. Its EchoPark digital platform further supports an omnichannel retail strategy aligned with evolving consumer preferences. Notably, Sonic has raised its dividend eight times over the last five years, underscoring consistent shareholder returns.
Sonic currently carries a Zacks Rank #2 (Buy). The Zacks Consensus Estimate for 2026 and 2027 sales implies year-over-year growth of 5% and 8%, respectively. The consensus mark for Sonic’s current and next year EPS has moved north by 13 cents and 10 cents, respectively, over the past 30 days.
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Lithia stands out as one of the most acquisitive and strategically disciplined auto retailers in the United States. The company added $2.4 billion in annualized revenues through acquisitions in 2025 and continues to target $2-$4 billion in annual acquired revenues in 2026, with a deliberate focus on large, high-performing stores in the high-profitability Southeast and South-Central markets.
Beyond physical expansion, Lithia's digital platforms— Driveway and GreenCars— enable customers to buy, sell and service vehicles online, supporting an omnichannel strategy aligned with shifting consumer preferences. Its North American JV sale to Pinewood AI has further streamlined operations, unified its technology platform and accelerated delivery capabilities. Lithia also maintains a strong shareholder return track record, with a five-year annualized dividend growth rate of 11.56%, reflecting confidence in its long-term earnings trajectory.
Lithia currently carries a Zacks Rank #3 (Hold). The Zacks Consensus Estimate for 2026 and 2027 sales implies year-over-year growth of 3% and 17%, respectively. The consensus mark for LAD’s current and next year EPS has moved north by 11 cents and 43 cents, respectively, over the past 30 days.
Why Haven't You Looked at Zacks' Top Stocks?Since 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year.
Today you can access their live picks without cost or obligation.
See Stocks Free >>
Join us on Facebook: https://www.facebook.com/ZacksInvestmentResearch/
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
The Zacks Electronics - Manufacturing Machinery industry players like Kulicke and Soffa Industries, Ultra Clean Holdings and Veeco Instruments are benefiting from massive investment in AI infrastructure. Hyperscalers and cloud providers are expanding data center capacity, driving demand for leading-edge logic chips, high-bandwidth memory (HBM), advanced packaging and optical networking solutions.
As AI processors become more complex, advanced packaging technologies have become a major investment area. More advanced process technologies, heterogeneous integration, higher process intensity and sophisticated packaging require additional deposition, etch, annealing, bonding and metrology equipment. Strong growth in memory equipment demand bodes well for industry players.
Industry DescriptionThe Zacks Electronics - Manufacturing Machinery industry comprises companies that provide a range of solutions to address the needs of wafer processing facilities, as well as device packaging and test facilities, and semiconductor manufacturing processes. The solutions offered by the industry participants include thin-film processing systems, photonics, process-control tools (that perform macro defect inspections and metrology), metal-organic chemical vapor deposition, advanced packaging lithography, wet etch and clean, laser annealing, and 3D wafer inspection systems.
A few industry participants also offer micro-contamination control products and advanced material-handling solutions. Contamination-free transportation, storage and delivery of materials have gained immense significance in recent times.
3 Trends Shaping the Future of the Electronics IndustryMiniaturization Enhances Prospects: Industry participants are benefiting from the ongoing transition in semiconductor manufacturing technology. The demand for advanced packaging, which enables the miniaturization of electronic products, remains strong. The consistent shift to smaller dimensions, increasing complexity in transistor design and the rapid adoption of new device architectures, such as FinFET, 3D NAND and GAA, along with the increasing utilization of new manufacturing materials to increase transistor and bit density, are driving the demand for solutions provided by the industry players.
Moreover, the emergence of techniques like wafer-level packaging is driving the need for a high-purity manufacturing environment free of contaminants. The rising demand for clean processing, as well as wafer carrier cleaning and conditioning tools, is a key catalyst for industry participants.
Complex Process Driving Demand: The requirement for faster, more powerful, compact and energy-efficient semiconductors is expected to increase rapidly with emerging applications, including AI, high-performance and cloud computing, smartphones, wearable technology, self-driving vehicles, the Internet of Things (IoT), gaming and virtual reality, and smart healthcare.
Semiconductor manufacturers like Intel, Samsung and Taiwan Semiconductors are primarily looking to maximize manufacturing yields at lower costs. This is making semiconductor manufacturing processes more complex and driving the demand for solutions offered by industry participants. The rapid adoption of IoT-supported factory automation solutions is another contributing factor. The increasing deployment of 5G and the growing demand for edge computing are other key catalysts.
DRAM & HBM Demand Strong: Memory has shifted from being a bottleneck to a major investment opportunity. Memory manufacturers are expanding both greenfield fabs and existing facilities to increase AI server capacity. HBM is emerging as one of the strongest secular growth drivers due to its critical role in AI accelerators and high-performance computing.
As GPUs become more powerful, memory bandwidth has become a key bottleneck, prompting memory manufacturers to aggressively expand HBM capacity. The broader DRAM market is also poised for sustained growth as AI applications require significantly larger memory capacity.
Zacks Industry Rank Indicates Bullish ProspectsThe Zacks Electronics - Manufacturing Machinery industry is housed within the broader Zacks Computer and Technology sector. It carries a Zacks Industry Rank #4, which places it in the top 2% of more than 250 Zacks industries.
The group’s Zacks Industry Rank, which is the average of the Zacks Rank of all the member stocks, indicates bullish near-term prospects. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than two to one.
The industry’s position in the top 50% of the Zacks-ranked industries is a result of the positive earnings outlook for the constituent companies in aggregate. Looking at the aggregate earnings estimate revisions, analysts appear optimistic about this group’s earnings growth potential. Since Jan. 31, 2026, the industry’s earnings estimates for 2026 have increased 48%.
Given the positive industry outlook, there are a number of stocks worth buying. However, before we present the stocks you may want to consider for your portfolio, let us take a look at the industry’s recent stock-market performance and valuation picture.
Industry Beats Sector & S&P 500The Zacks Electronics - Manufacturing Machinery industry has outperformed the broader Zacks Computer and Technology sector and the S&P 500 over the past year.
The industry has jumped 233.1% over this period compared with the S&P 500’s return of 23.4% and the broader sector’s appreciation of 37.1%.
Industry's Current ValuationOn the basis of the trailing 12-month EV/EBITDA ratio, which is a commonly used multiple for valuing Electronics - Manufacturing Machinery companies, we see that the industry is trading at 42.52X compared with the S&P 500’s 18.23X. The industry is trading above the sector’s trailing 12-month EV/EBITDA of 19.7X.
Over the last five years, the industry has traded as high as 44.67X and as low as 4.03X, with the median being 12.7X.
3 Electronics Stocks to Buy Right NowKulicke and Soffa: This Zacks Rank #1 (Strong Buy) is riding on strong demand for Thermo-Compression Bonding (TCB). You can see the complete list of today’s Zacks #1 Rank stocks here.
Kulicke and Soffa expects TCB revenues to exceed $100 million in fiscal 2026. The company is expanding production capacity to support approximately $400 million in Advanced Solutions revenue, positioning KLIC to capitalize on the AI packaging cycle.
An expanding portfolio bodes well for Kulicke and Soffa’s prospects. Introduction of new solutions, including the Asterion-TW power semiconductor platform, ProMEM memory suite and advanced dispense products, is noteworthy. KLIC is increasing investments in hybrid bonding and panel-level packaging. These initiatives position the company to capture future demand across HBM, DRAM, power semiconductors and next-generation heterogeneous integration.
The Zacks Consensus Estimate for Kulicke and Soffa Industries’ fiscal 2026 earnings has been unchanged at $3.34 per share over the past 30 days. Shares have jumped 170.6% year to date.
Ultra Clean Holdings: This Zacks Rank #1 company believes the semiconductor industry is in the early stages of a multiyear AI-driven expansion, supported by hyperscaler investments, leading-edge foundry logic, HBM and advanced packaging demand. UCTT expects momentum to strengthen through the second half of 2026 and into 2027 as customers increase wafer fab equipment spending and fab utilization.
Ultra Clean’s existing manufacturing network supports approximately $3 billion in annual revenues and can scale to roughly $4 billion with only modest incremental capital investment. As volumes rise, UCTT expects higher factory utilization, better operating leverage and continued margin expansion, supported by its UCT 3.0 operational strategy and digital transformation initiatives.
The Zacks Consensus Estimate for Ultra Clean Holdings’ 2026 earnings has climbed 4.7% to $2.46 per share over the past 30 days. Shares have skyrocketed 328.1% on a year-to-date basis.
Veeco: This Zacks Rank #1 company continues to benefit from strong demand in advanced packaging, logic, memory and silicon photonics, with management highlighting sustained order momentum and increasing visibility into 2027. Veeco expects AI infrastructure investments to drive durable multiyear growth across its semiconductor portfolio.
Veeco secured more than $250 million in orders for MOCVD, wet processing and Ion Beam Deposition systems supporting indium phosphide laser manufacturing for AI data centers. Deliveries begin in 2026 and accelerate significantly in 2027, reinforcing the company's leadership in optical networking technologies as data centers transition from copper interconnects to optics.
The company is increasing manufacturing capacity for Advanced Packaging and Ion Beam Deposition systems while continuing to expand opportunities in HBM, EUV mask blanks, GaN power devices and advanced annealing. Veeco expects these technologies to drive meaningful market expansion through 2030, providing multiple long-term growth drivers beyond the current AI cycle.
The Zacks Consensus Estimate for Veeco’s 2026 earnings has been steady at $1.65 per share over the past 30 days. Shares have appreciated 149% year to date.
Why Haven't You Looked at Zacks' Top Stocks?Since 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year.
Today you can access their live picks without cost or obligation.
See Stocks Free >>
Join us on Facebook: https://www.facebook.com/ZacksInvestmentResearch/
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Friday morning before market open, Intuitive Machines (LUNR 2.25%) investors were digesting a double-digit fall in the space stock over the preceding days. The monster new equity in the sector -- Space Exploration Technologies, of course -- was experiencing quite the bear run, and was dragging down other industry titles.
Intuitive Machines couldn't escape this. At that point, its share price had eroded by nearly 16% week to date, according to data compiled by S&P Global Market Intelligence.
The inescapable force Intuitive didn't have any price-dragging news of its own this week (at least as of this writing), so its stock price slide was clearly a by-product of SpaceX's swoon. The dynamic with the latter company isn't unusual. Large initial public offerings (IPOs) -- and SpaceX's is massive -- tend to trigger high expectations.
Image source: Getty Images.
Also, the company is soaringly ambitious, and not only in its namesake field of space exploration. It also has considerable involvement in artificial intelligence (AI) and the infrastructure that supports it, and owns social media site X (formerly Twitter).
SpaceX made an impressive market debut, but subsequently, the stock obeyed gravity. Many realized that the company will need mountains of capital to develop and maintain some of its businesses -- neither rockets nor AI data centers come cheap -- and profitability might be elusive.
Meanwhile, in the run-up to the IPO, the space sector rallied. Much of this came from "a rising tide lifts all boats" philosophy, plus the idea that SpaceX's existing business partners, like Intuitive, would benefit from their peer's increased spending after those IPO proceeds landed in the company's coffers.
Today's Change
(
-1.00
%) $
-1.54
Current Price
$
153.00
An intuitive play... eventually I view the "space rout" as more of a correction -- many companies in the industry have high valuations but have yet to prove they can consistently book meaningful profits. Any overvalued stock is ripe for a sell-off.
Having said that, Intuitive has more potential than most, as evidenced by its impressive top-line growth lately. I feel that after the "SpaceX drag" runs its course, investors should consider buying Intuitive again.
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Intuitive Machines. The Motley Fool has a disclosure policy.
The drug and biotech sector is in a recovery mode, after going through a difficult period between 2022 and 2024, backed by strong quarterly results, surging mergers and acquisitions (M&A) activity and pipeline and regulatory successes.
Innovation remains a key growth driver, with high-interest areas such as obesity treatments, next-gen oncology drugs, immunology, gene editing, cell therapies and RNA-based medicines drawing strong investor focus. However, the sector continues to face challenges, including pipeline setbacks, looming patent expirations, regulatory uncertainty, drug-pricing pressure and broader macro challenges.
Despite these headwinds, accelerating innovation, the expanding use of artificial intelligence in drug discovery and development, encouraging regulatory and clinical pipeline updates and the resurgence of M&A activity point to a constructive growth outlook for 2026.
Amid the improving backdrop, the Zacks Medical-Drugs industry is showing promising trends backed by a focus on innovation and positive pipeline/regulatory developments. In this scenario, Indivior Pharmaceuticals, Aurinia Pharmaceuticals, Ironwood Pharmaceuticals, Altimmune and Marker Therapeutics may prove to be good additions to one’s portfolio.
Industry Description
The Zacks Medical-Drugs industry comprises small and some medium-sized drug companies that make medicines. We have a separate industry outlook discussion on big drugmakers. Small drugmakers have a limited portfolio of marketed drugs or no commercial drugs at all. Some drugmakers are dependent on just one marketed drug or pipeline candidate.
For such companies, upfront or milestone payments from collaboration partners — in most cases, their larger counterparts — are the main sources of revenues. These companies need ample free cash flow to fund their R&D costs.
Factors Shaping the Future of the Medical-Drugs IndustryPipeline Success: The success or failure of key pipeline candidates in clinical studies can significantly drive the stock price of industry players. Successful innovation and product line extensions in important therapeutic areas and strong clinical study results may act as important catalysts for the stocks.
Innovation is at its peak with key spaces like rare diseases, next-generation oncology treatments, obesity, immunology and neuroscience attracting investor attention.
Strong M&A Activity: These companies regularly seek external partners and collaborators for complementary strengths. A partnership deal with a popular drugmaker is a good sign about the potential of small pharma companies, especially when an equity investment is included in the deal. M&A deals are in full swing in the sector, signaling growth. This year has already seen multiple multi-billion-dollar deals. The trend is shifting more toward smaller and mid-size “bolt-on” strategic acquisitions rather than mega-mergers.
Investment in Technology for Innovation: For smaller companies, succeeding in a shifting global market and evolving healthcare landscape requires adopting innovative business models, investing in new technologies and increasing investments in personalized medicines. Over the past few years, scientific and technological advancements have made it possible to develop personalized therapies.
Other than that, adoption and information exchange through the meaningful use of health IT, development of therapies that improve overall patient outcomes and investment in developing and emerging markets are some of the key priorities for drug companies. Artificial intelligence and machine learning techniques are being used for the rapid advancement of drug discovery and target identification processes.
Pipeline Setbacks: The smaller companies have their share of risk in the form of unstable cash flows. Also, the failure of key pipeline candidates in pivotal studies and regulatory and pipeline delays can be huge setbacks for these smaller companies and significantly hurt their share prices.
Zacks Industry Rank Indicates a Short-Term Gloomy PictureThe group’s Zacks Industry Rank is basically the average of the Zacks Rank of all the member stocks.
The Zacks Medical-Drugs industry currently carries a Zacks Industry Rank #149, which places it in the bottom 40% of the 247 Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Before we present you with a few top-ranked stocks to capitalize on the prospects of the small and medium-sized drugmakers’ space, let’s take a look at the industry’s recent stock-market performance and the valuation picture.
Industry Versus S&P 500 and SectorThe Zacks Medical-Drugs industry is a huge 133-stock group within the broader Medical sector. The industry has outperformed the S&P 500 but underperformed the Zacks Medical sector so far this year.
Stocks in this industry have collectively declined 0.5% so far this year against the Zacks Medical sector’s increase of 1.9%. The Zacks S&P 500 composite has declined 2% in the said time frame.
Industry's Current ValuationBased on the trailing 12 months price-to-sales ratio (P/S TTM), which is a commonly used multiple for valuing these small drugmakers, the industry is currently trading at 2.26, compared with the S&P 500’s 5.94 and the Zacks Medical sector's 2.45.
Over the last five years, the industry has traded as high as 3.36, as low as 2.05 and at the median of 2.49.
5 Drug Stocks to Bet OnIndivior Pharmaceuticals:North Chesterfield, VA-based Indivior’s commercial portfolio is anchored by its flagship product, Sublocade, a first-in-class long-acting injectable treatment for moderate-to-severe opioid use disorder, alongside Suboxone film and tablets, a daily buprenorphine/naloxone formulation for opioid dependence. Sublocade accounts for the majority of Indivior’s revenues.
Indivior remains a leader in opioid use disorder treatment, with Sublocade increasingly driving growth. The product continues to gain traction through record patient starts, growing prescriber adoption, and a leading share of the U.S. long-acting injectable market. The company is also benefiting from a major restructuring program, supporting strong earnings and EBITDA growth. Additionally, the large and persistent opioid addiction market provides a favorable long-term growth opportunity.
However, Indivior's internal pipeline has suffered setbacks. In 2026, the company decided not to advance INDV-6001 into phase III development and also halted the internal development of INDV-2000 for opioid use disorder after disappointing phase II data.
The stock of Indivior has risen 15.5% so far this year. The consensus estimate for 2026 earnings has risen from $3.33 per share to $4.05 per share over the past 60 days. The company has a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Aurinia Pharmaceuticals: Canada-based Aurinia Pharmaceuticals makes medicines to treat autoimmune, kidney and rare diseases. It presently markets Lupkynis (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. The company recorded strong Lupkynis sales growth of 24% in the first quarter of 2026. Management expects total revenues to reach $315-$325 million in 2026, representing double-digit growth over 2025 levels. Lupkynis is emerging as a standard-of-care treatment for lupus nephritis.
Aurinia is also developing aritinercept, a potentially best-in-class dual inhibitor of BAFF and APRIL cytokines. It has the potential to treat a wide range of autoimmune diseases and is now in clinical development for three potential indications.
Aurinia Pharmaceuticals has a Zacks Rank #2 (Buy). The consensus estimate for 2026 earnings has been stable at 86 cents per share over the past 60 days. The stock has risen 16.7% so far this year.
Altimmune: Gaithersburg, MD-based Altimmune is a late clinical-stage biotech focused on making therapies for liver diseases. Altimmune’s lead pipeline candidate, pemvidutide, a balanced 1:1 glucagon/GLP-1 dual receptor agonist, has a differentiated mechanism of action and “pipeline in a product” potential for treating liver diseases. It is being developed to treat serious liver diseases like metabolic dysfunction-associated steatohepatitis (“MASH”), alcohol use disorder (“AUD”) and alcohol-associated liver disease (“ALD”), which have a significant unmet need.
A phase III study for MASH patients with moderate-to-severe liver fibrosis is expected to start in 2026. For the AUD and ALD indications, phase II studies are ongoing. Multiple catalysts are expected in 2026, including phase III initiation for MASH and phase II top-line data for AUD. Its promising pipeline makes it an attractive licensing or takeover target.
The stock of Altimmune has declined 18.3% so far this year. The consensus estimate for 2026 loss has narrowed from $1.00 per share to 69 cents per share over the past 60 days. The company has a Zacks Rank #2.
Ironwood Pharmaceuticals:Cambridge, MA-based Ironwood Pharmaceuticals’ primary asset is Linzess, a leading treatment for irritable bowel syndrome with constipation and chronic idiopathic constipation. The drug continues to demonstrate healthy prescription demand growth and has treated millions of patients since launch. Management expects U.S. Linzess net sales to reach $1.125-$1.175 billion in 2026
Ironwood is also regularly getting approvals to expand Linzess' label, which is also supporting sales growth. Linzess is also well protected by patents and is not expected to face generic competition before March 2029.
Apraglutide, Ironwood's lead pipeline candidate for treating short bowel syndrome with intestinal failure (SBS-IF), represents a potentially game-changing growth opportunity for the company. Ironwood recently reached an agreement with the FDA on the design of a confirmatory phase III study required to support regulatory approval of apraglutide in SBS-IF. Management believes that, if successfully developed and approved, apraglutide has the potential to achieve blockbuster status.
The stock of Ironwood has risen 16% so far this year. The consensus estimate for 2026 earnings has risen from 88 cents per share to $1.04 per share over the past 60 days. The company has a Zacks Rank #2.
Marker Therapeutics: This Houston, TX-based cancer biotech is making next-generation T cell therapies for hematological malignancies and solid tumors, leveraging its multi-antigen recognizing (MAR) T cell platform. Marker is rapidly progressing a phase I APOLLO study on lead candidate, MT-601, in patients with relapsed or refractory B-cell lymphoma.
Updated data from the study reported last August demonstrated encouraging clinical activity with a 66% objective response rate in relapsed non-Hodgkin lymphoma, including durable complete responses, with a favorable safety profile across evaluated doses. A data update from the APOLLO study is expected in the second quarter of 2026. Clinical studies on MT-601 in pancreatic cancer are also expected to begin in the second quarter of 2026.
Marker is also conducting a phase I study on its off-the-shelf candidate, MT-401 and entered into a strategic manufacturing collaboration with Cellipont to scale up production of MT-601. The stock of Marker Therapeutics has declined 12.1% so far this year. The consensus estimate for 2026 loss per share has narrowed from $1.19 to $1.17 over the past 60 days. The company has a Zacks Rank #2.
Why Haven't You Looked at Zacks' Top Stocks?Since 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year.
Today you can access their live picks without cost or obligation.
See Stocks Free >>
Join us on Facebook: https://www.facebook.com/ZacksInvestmentResearch/
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
NIQ (NYSE: NIQ), a leading consumer intelligence company, today revealed new analysis presented at The Consumer Goods Forum (CGF) Global Summit showing that ne
With the price of its favorite precious metal declining, Eldorado Gold (EGO +2.32%) stock has taken it on the chin over the past few trading days. According to data compiled by S&P Global Market Intelligence, the mining company's shares were down almost 13% week to date as of early Friday morning.
Tarnished metal Gold is currently on a losing streak due to several factors. Chief among these is the growing expectation from analysts and economists that the Federal Reserve (Fed) will raise interest rates in the coming months. After all, inflation is still a problem -- not least because of the economic fallout of the war with Iran -- and the primary remedy for a central bank is higher rates.
Image source: Getty Images.
As rates rise, the attractiveness of non-yielding assets such as gold declines, which in turn helps fuel the sell-offs we've seen over the past few days. Compounding that, as the temperature seems to be cooling in the U.S.-Iran negotiations to end the conflict, many investors consider precious metals less appealing as safe-haven plays.
Another factor was that the gold price dipped below $4,000 per ounce on Wednesday, to its lowest level since late last year. Market players can get spooked when an asset dips below a certain price; although the actual decline might not be dramatic, it often serves as a reminder that the investment is stumbling.
Today's Change
(
2.32
%) $
0.69
Current Price
$
30.43
Late-week bounce As of this writing, gold had bounced above the $4,000 line near the end of the week, and Eldorado bounced along with it.
I'm not convinced that this bear run in the precious metal is over, however, as I feel we haven't seen the last of discouraging developments on inflation, and the war seems to be lurching toward a conclusion. I'd remain wary of precious metals like gold and the mining companies that specialize in it, like Eldorado.
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
Cerebras Systems (CBRS 7.54%) launched one of the year's most exciting technology initial public offerings just a month ago. The company, an artificial intelligence (AI) chip player that aims to rival market giant Nvidia, raised $5.5 billion for the biggest IPO of the year at that point. (Space Exploration Technologies, or SpaceX, went on to surpass that a few weeks later when it completed the largest IPO ever.)
On its first day of trading, Cerebras saw its shares soar 68%, but since that day, they've lost more than 25%. The company hasn't reported unfavorable news that could have prompted this movement, but it's important to keep in mind that investors have grown increasingly cautious regarding AI stocks. The industry has led gains in the S&P 500 over the past few years, and now, investors are watchful for any signs of a slowdown.
So far, AI companies of all sorts -- from chip designers to cloud service providers -- have spoken of soaring demand and revenue. And that's very positive. But another earnings metric is also important to watch. In fact, Cerebras' first earnings report since its IPO just highlighted it -- and this metric is a crucial point that all AI investors shouldn't ignore.
Image source: Getty Images.
Cerebras' big chip First, a quick summary of the Cerebras story so far. The company has designed a chip that it says may even beat the speed of Nvidia's top graphics processing units (GPUs). Cerebras' technology involves packing processors onto one giant chip rather than linking together smaller GPUs. The company's Wafer-Scale Engine (WSE) is 58 times larger than Nvidia's B200 chip and has more than 2,000 times the memory bandwidth of two of those Nvidia chips linked together as a package. Cerebras says this size results in incredible speed.
The company has seen revenue soar, and this was confirmed in its earnings report, with revenue surging 92% in the first quarter to a record of more than $191 million. The company also signed a multi-year deal with OpenAI that's worth more than $20 billion and has inked a partnership with Amazon's Amazon Web Services (AWS) to offer customers access to its chips. Right now, Cerebras is very dependent on a limited number of customers, but the AWS partnership could help the company broaden its reach.
Today's Change
(
-7.54
%) $
-13.74
Current Price
$
168.52
A key forecast Now, let's consider the metric all AI investors -- whether you invest in Cerebras or not -- should look to. And that's where Cerebras may have disappointed investors this quarter. This is the company's forecast for gross margin. In the first quarter, Cerebras reported core gross margin of 47%. (The core figure is non-GAAP and excludes certain items.) For the current quarter, Cerebras expects core gross margin in the range of 36% to 38%, which clearly shows a narrowing from the first three months of the year.
It's important for an AI company to generate sales gains, but today, investors should focus on profitability on sales -- and that's seen in gross margin figures. Here, we can see Cerebras shifting toward lower profitability on sales in the second quarter of the year. It's too early to draw major conclusions, as this may be a temporary shift and margins may progressively improve. But it is something important to watch, and ideally, investors should aim to invest in AI players that are seeing steady high margins -- such as Nvidia, with a gross margin of more than 70% -- or that are progressively expanding their margins.
Of course, it's also important to put the gross margin figure into perspective. If a company is ramping up a new product, it might see profitability dip temporarily while it establishes certain production processes, for example. So, while you should aim to invest in a company with increasing or steadily high margins, there may be very logical reasons for a dip here and there.
It's clear that AI is driving revenue growth at many companies, from Cerebras to market giants like Nvidia or Amazon. But in order to choose lasting AI winners, investors shouldn't ignore gross margin, a metric that could determine how profitable the company might become over the long run.
The question hanging over this year's listing pipeline was simple: Could public markets absorb three trillion-dollar technology floats in quick succession? SpaceX went first. The early read is not encouraging.
Elon Musk's rocket company listed on 12 June and raised more than $85 billion, the largest debut on record.
The stock has since gone into reverse. It closed at $153 on Thursday after topping $225 last week. Musk has lost his trillionaire status in the process.
That sequence appears to have concentrated minds inside OpenAI.
OpenAI is now minded to wait
The company is leaning toward pushing its listing from late this year into 2027, sources told The New York Times. Its advisers spent the past week warning that a float might not draw enough demand while tech shares slide.
OpenAI had hired bankers and lawyers with a third or fourth quarter listing in view. Altman wanted a $1 trillion valuation out of it.
Advisers offered him a choice. Wait until 2027 for the trillion-dollar figure, or accept less for a faster deal.
He called any cut a "nonstarter," one person in contact with him told the Times. So the timing slips rather than the price.
Numbers behind the caution
OpenAI was last valued at $852 billion. It reported roughly $13 billion in revenue last year against a $21 billion net loss. Projected spending on compute and hardware runs to $600 billion through 2030.
That gap explains the scramble for fresh income.
The company is testing ads inside ChatGPT and building commerce tie-ups with Shopify and Stripe. It is also trimming money-losers, including the Sora video app.
Internal nerves predate the public wobble. Chief financial officer Sarah Friar had already raised concerns about this year's finances, according to the Wall Street Journal.
Anthropic changes the maths
OpenAI is not floating into an empty room. Its main rival filed confidentially on 1 June for a debut expected late this year.
Anthropic raised money at a $965 billion valuation in late May. That figure overtook OpenAI's private mark for the first time.
So Altman faces a rival carrying a richer price tag and a market that has just punished the biggest name to test it. Waiting buys time for sentiment to recover. It also hands Anthropic the chance to reach public investors first.
'Realism' sets in
Altman has not blinked on valuation. He has blinked on timing. The trillion-dollar number stays. The date moves. Whether 2027 looks friendlier than 2026 is the call he is now making.
Two weeks ago, Elon Musk's Space Exploration Technologies (SpaceX)(SPCX 1.00%) cemented its name in the record books. Including the overallotment option exercised by underwriters, SpaceX raised $85.7 billion from its initial public offering (IPO), nearly tripling the $29.4 billion raised by overseas oil titan Saudi Aramco in December 2019.
But investing on Wall Street isn't about where a stock has been -- it's about where it'll head next. Although historical precedent can't guarantee what's to come, history does tend to rhyme. Using history as a guide, here's my prediction for SpaceX's share price by the end of 2027.
Image source: Getty Images.
SpaceX's intangibles are its biggest catalysts and question marks Arguably, the leading catalyst for SpaceX is retail investor euphoria, which is incredibly difficult to quantify. Retail investors have flocked to this record-breaking IPO for a variety of reasons:
SpaceX is at the forefront of two of the largest addressable opportunities, artificial intelligence (AI) and the space economy. CEO Elon Musk has a track record for generating outsize investment returns at Tesla. SpaceX's sales growth should be parabolic over the next few years. To be clear, this means only the S&P 500 will exclude SpaceX shortly after its IPO.
FTSE Russell adds eligible megacap IPOs after the close of the 5th trading day.
Nasdaq adds them about 15 trading days after listing.
The S&P 500 kept its rules, so SpaceX waits the full...
-- Hedgeye (@Hedgeye) June 4, 2026 Additionally, the company should receive an early boost from recently amended index inclusion rules. Prior to SpaceX's debut, Nasdaq Global Indexes reshaped the criteria for Nasdaq-100 inclusion. The low float requirement was shelved, and the time to inclusion for megacap companies was slashed from around three months to just 15 trading sessions.
The U.S. Russell Equity Indexes followed suit with amended fast-track inclusion criteria, as well.
Fast entry into the Nasdaq-100, Russell 1000, and Russell 3000 can provide tens of billions of dollars in buying demand from index funds.
Image source: Getty Images.
Caveat emptor, retail investors While SpaceX isn't without catalysts, history strongly suggests shares will head substantially lower.
To begin with, large-scale IPOs tend to struggle mightily in their first year as public companies. According to research published by Truist Financial, the average year-one drawdown for the 30 most-hyped, tech-driven IPOs since May 2012 is 55%! What this figure tells investors is that the initial euphoria following a company's debut fades quickly.
Moral of the story-do NOT chase hot IPOs
Year-1 average drawdown = 55%
Year-1 median drawdown = 54%
Table: Truist pic.twitter.com/xt864JD4Xh
-- Puru Saxena (@saxena_puru) June 3, 2026 SpaceX's valuation is also completely unjustified. Based on what history tells us, no company at the forefront of a game-changing technology has ever sustained a price-to-sales (P/S) ratio above 30 for an extended period. As of the closing bell on June 24, SpaceX is valued at a P/S ratio of 109!
The company's staggered lockup schedule is another cause for concern. Instead of a 180-day lockup period where insiders can't sell their shares, SpaceX settled on an accelerated unlock schedule with several time- and performance-based markers. Insiders will be able to cash out at retail investors' expense, leaving them holding the bag for an expensive, unproven, and unprofitable business.
All of these historical factors suggest that SpaceX's year-one max drawdown will be larger than the average pullback of 55%.
While I'm inclined to believe retail investors' allegiance to Musk can support an outsize premium for SpaceX, its egregious valuation and the upcoming lockup period are red flags that can't be ignored. I expect SpaceX to hover around or just below the $1 trillion market cap mark by the end of 2027, placing its share price in the neighborhood of $75.
Sean Williams has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Tesla and Truist Financial. The Motley Fool recommends Nasdaq. The Motley Fool has a disclosure policy.
On Jan. 12, 2026, Apple (AAPL 6.41%) and Alphabet (GOOGL 0.30%) (GOOG 0.83%) announced a deal that will see Google's Gemini AI model power a smarter Siri. The price tag is rumored to be roughly $1 billion a year, though neither company has confirmed terms.
On its face, it looks like a confirmation that Apple is painfully behind in the AI space race. I disagree. I think Apple is the winner. Here's why.
Image source: Getty Images.
What Google gets out of the deal Google gets a high-margin licensing fee on a model it already built, so there's no major new spending attached. It also gets bragging rights of a sort -- Apple, a company known for its obsession with quality, picked Gemini over OpenAI's ChatGPT and Anthropic's Claude. That means something.
On the other hand, $1 billion a year is a drop in the bucket for a company with annual sales of more than $400 billion. And it's only 5% of the payment Google makes to Apple for the privilege of remaining the default search engine on the iPhone.
Today's Change
(
-0.30
%) $
-1.05
Current Price
$
344.24
Why the real power stays with Apple The disparity here is revealing. If Google lost that default search slot, it would be locked out of the search traffic from more than 1.5 billion of the most valuable devices on earth -- a gut punch to its core business. If, on the other hand, Apple swapped Gemini out for OpenAI's GPT, Anthropic's Claude, or even China's DeepSeek, the average iPhone owner would likely not notice.
It shows that AI models are more or less a commodity -- an interchangeable part Apple can shop for and replace, while Apple's hold on its customers is anything but.
Today's Change
(
-6.41
%) $
-18.78
Current Price
$
274.30
Siri gets smarter without Apple footing the R&D bill Internal evaluations reportedly showed Siri flubbing complex requests about a third of the time. It's clear that by incorporating Gemini, Apple will be able to greatly improve its products and the user experience.
Apple needed a fix, and it got it. $1 billion a year isn't cheap, but it pales in comparison to the investment Google has pumped into developing Gemini. Apple gets an immediate fix while it works to perfect its own in-house model.
And -- in stark contrast to the rest of big tech -- it does this with remarkable discipline. Apple's AI capital spending in 2025 was about $12.7 billion. Alphabet spent roughly $90 billion.
In my view, Apple has positioned itself perfectly to reap the rewards of state-of-the-art AI without most of the cost of creating it. So, while many people say Apple is falling behind in AI, I say it's right where it needs to be. I think this deal confirms it.
Amazon (AMZN 3.38%) has a lot going for it. The company has a huge e-commerce business that has transformed how people shop and disrupted the brick-and-mortar retail model. And its Amazon Web Services (AWS) is the biggest cloud computing company in the world, with a market share of nearly 30%.
The company also is emerging as a key player in satellite internet service. Its Amazon Leo is seeking to compete with Starlink, the satellite internet service of Space Exploration Technologies, or SpaceX, in operating networks of low-orbit satellites to provide mobile service and internet to underserved and rural areas.
Despite all this, Amazon shares aren't getting much love. Of all the members of the "Magnificent Seven" cohort, it has been the worst-performing stock, gaining only 33% over the last five years.
AMZN data by YCharts.
Why is Amazon struggling despite everything it has going for it? Let's take a look.
The headwinds facing Amazon The company's e-commerce business is huge, but it's also very expensive. The problem is that it doesn't make much money despite generating hundreds of billions in sales every year.
In the first quarter, it had $181.5 billion in sales -- an impressive figure. Of that, $143.9 billion came from Amazon.com's domestic and international sales. But those sales also recorded $134.24 billion in expenses, leaving a small profit margin of just 6.7%.
Image source: The Motley Fool.
AWS is much more profitable and growing faster. In the first quarter, its sales were $37.58 billion, up 28.4% from a year ago. The segment generated $14.16 billion in profits, giving it a much healthier profit margin of 37.6%.
AWS is the most appealing part of Amazon's growth story right now. Grand View Research estimates that the cloud computing market is worth $1.1 trillion this year, up from $943 billion in 2025. And it forecasts that the industry will grow to $3.35 trillion by 2033, with a compound annual rate of 16%.
Today's Change
(
-3.38
%) $
-7.92
Current Price
$
226.34
That's why hyperscalers like Amazon are building up their cloud computing capacity and buying GPUs from companies like Nvidia hand over fist. It had $131.8 billion in capital expenditures (capex) in 2025 and estimates it will spend $200 billion this year.
That's a scary number for many investors. AI chips such as GPUs are incredibly powerful, and you need to bundle hundreds of them in data centers to train and run AI programs. But GPUs also have a short lifespan because companies like Nvidia are constantly working to improve them and make them more powerful. So it's only natural for investors to question if Amazon and its peers can expect a reasonable return on their investments.
Amazon doubles down on AI According to Reuters, CEO Andy Jassy projected that AWS will reach $600 billion in annual sales within a decade, doubling his previous estimate. At that rate, the segment would grow by about 17% per year, based on AWS' 2025 sales of $128.7 billion.
Jassy said AI provides a "very unusual opportunity to build this very large business, and we have very clear and significant demand signals. We're not just spending the $200 billion of capex because we're hoping AI is going to be big."
The size of the company's bet on AI is facing skepticism from Wall Street today, a major reason it is underperforming the rest of the Magnificent Seven. I think Amazon stock is still a buy, but only if you have a long-term investment horizon.
Patrick Sanders has positions in Nvidia. The Motley Fool has positions in and recommends Alphabet, Amazon, Apple, Meta Platforms, Microsoft, Nvidia, and Tesla. The Motley Fool has a disclosure policy.
Is the AI capex boom built to last, or is consumer tech running out of room? Sunil Garg breaks down the bull and bear cases for the tech and memory markets, explaining why upstream infrastructure is thriving while Big Tech and software platforms are facing mounting pressure.
Advanced Micro Devices NASDAQ:AMD stock has surged more than 130% this year, but Wall Street is still chasing the stock higher.
In June alone, Barclays, UBS, Mizuho and Bernstein all raised their price targets on the chipmaker as analysts are no longer treating AMD as just a second-place GPU challenger to Nvidia.
They are increasingly arguing that CPUs are becoming an AI story and the driver is agentic AI, or AI systems that do more than answer one prompt.
Barclays was one of the first major firms to put a bigger number on the CPU opportunity.
Analyst Tom O’Malley raised his AMD price target to $665 from $500 and kept an Overweight rating.
His core argument was that “CPU-to-GPU ratios are narrowing as CPU demand reaches new levels in the rapidly expanding world of agentic AI,” adding that AMD is “best positioned to benefit from this transition”.
The CPU-to-GPU ratio simply means how many central processors are needed for every graphics processor inside AI systems.
Early AI spending was dominated by GPUs because training large models required enormous parallel computing power.
Agentic AI changes the mix because it needs more coordination, routing and software execution around those GPUs.
O’Malley’s model sees the standalone server CPU market approaching $200 billion by 2030.
UBS pushed the argument even further.
Analyst Timothy Arcuri raised his AMD target to $670 from $455 and kept a Buy rating.
That now stands above Barclays’ $665 call and makes UBS one of the most bullish voices on the stock.
The firm said it was “incrementally more constructive” on AMD as standalone CPU racks gain traction.
In plain English, UBS thinks customers are starting to buy CPU-heavy systems for AI workloads that do not rely only on GPU clusters.
That matters because AMD’s CPU business has often been overshadowed by its Instinct GPU ramp.
Investors are watching whether AMD can become a credible second source to Nvidia in AI accelerators. UBS is saying another part of the story may be hiding in plain sight: server CPUs.
Arcuri lifted his 2030 AMD server CPU revenue forecast to $50 billion from $41 billion.
Mizuho and Bernstein added a second layer to the bull case: scarcity.
Mizuho raised its AMD target to $615 from $515 and kept an Outperform rating, citing strong demand linked to agentic AI.
The firm also flagged that CPU and memory suppliers could remain supply-constrained into 2027.
That turns the story from pure demand into a supply-side argument.
If companies need more CPUs for AI workloads, and supply remains tight, pricing and revenue assumptions may have room to move higher.
Bernstein also raised its AMD target, lifting it to $600 from $525 while maintaining an Outperform rating.
The firm increased its 2030 server CPU market estimate to $223 billion from $137 billion, reflecting a much larger opportunity tied to agentic AI.
The caveat is valuation, as AMD’s average Wall Street price target still sits below where the stock recently traded, which means shares have already run ahead of broad consensus.
The next real tests are AMD’s Advancing AI event in July and Q2 earnings in early August.
SummaryAdvanced Micro Devices is rated a buy, driven by robust fundamentals and a compelling dual-engine growth thesis in both GPUs and CPUs.AMD's AI GPU position is strengthened by hyperscaler diversification needs, with multi-year, multi-gigawatt deals from Meta and OpenAI providing long-term demand visibility.CPU opportunity is underappreciated; AMD’s EPYC franchise benefits from AI infrastructure growth regardless of GPU winner, with CPU revenue share at a record 46.2%.Despite premium valuation (70x–113x P/E), visible catalysts—Helios, MI450, and CPU TAM expansion—and consistent EPS growth justify long-term Quality Growth positioning. Marvin Samuel Tolentino Pineda/iStock Editorial via Getty Images
On the surface, Advanced Micro Devices Inc. (AMD) does not look all that attractive at the moment. The recent share price appreciation and subsequent explosion of valuation premiums seem generous for a company that was late to the AI GPU
218 Followers
Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
Sneaker giant Nike (NKE 2.46%) has been a disaster over the past few years. Sales have been dropping as it cedes market share to competitors, and increased tariffs have made it challenging to improve profitability. As a result, the stock has plummeted 68% over the past five years, and it's now 21% lower than it was a decade ago.
The company brought in a new CEO last year, and it's making some progress, though management has admitted that conditions might get worse before they get better.
Has Nike finally reached the getting better part? Let's see what some of the updates could be when it reports earnings next week, and whether it makes sense to buy Nike stock right now.
Image source: Nike.
Getting back in the game Nike is still the premier athleticwear brand, with a wide lead over rivals. But no leader is immune to changing trends, and smaller companies have dug into the open holes where Nike wasn't playing its hardest game. The main culprit seems to be that Nike became too reliant on its top franchises and abandoned innovation in sport.
At the same time, it decided to cut ties with wholesalers to devote resources to its direct-to-consumer business. In hindsight, the fallout from that decision is obvious. Customers didn't see Nike products on wholesale partner shelves in stores like Dick's Sporting Goods and Macy's, and were instead introduced to smaller brands developing excellent products.
Today, Nike has made an about-face in these two areas, restarting wholesale partnerships and investing heavily in innovation. Specifically, it has changed its model and is bringing out new products, addressing the serious athlete at a faster pace.
In the 2026 fiscal third quarter (ended Feb. 28), sales were flat year over year, with a 5% increase in wholesale and a 4% decease in direct-to-consumer. It's still reeling from tariffs, and gross margin fell 1.3 percentage points from last year.
Today's Change
(
-2.46
%) $
-1.03
Current Price
$
40.79
As for guidance, management is expecting sales to drop 2% to 4% in the fourth quarter and sequential improvement in gross margin, although it is expected to be lower year over year. It anticipates that all activity for its "Win Now" turnaround plan will be completed by the end of the calendar year, and for improvement in the gross margin starting in the fiscal second quarter, when year-over-year comparisons for tariff impact will no longer be relevant.
What could happen on June 30? Nike is scheduled to provide fourth-quarter results on June 30, and the market is already expecting declining sales. If the report is better than expected, the stock will reflect that. The market will also take into account any changes in forward guidance.
Over the past year, Nike's stock has responded well to earnings only once. It gave up all of its gains with subsequent earnings reports.
NKE data by YCharts
That's why you can't time your investment based on one report. If you envision Nike getting back on track, now could be a good time to buy, although the stock is likely to go sideways until there's sustained progress.
Semiconductor chip export restrictions to China have cost Nvidia (NVDA 1.86%) billions in revenue. In a recent interview, CEO Jensen Huang admitted that Nvidia's chip market share in China has been wiped out. Speaking about Nvidia's share of the artificial intelligence (AI) chip market, Huang said, "Nvidia had ... 90-some-odd percent of the world's market share. Today in China, we have now dropped to zero."
China is a large and important market for Nvidia, but in the near term, the company hasn't missed a beat. Its new Vera central processing unit (CPU) is opening up a $200 billion addressable market that completely dwarfs its previous chip revenue in China.
Image source: The Motley Fool.
Vera CPU revenue expected to hit nearly $20 billion Last year, the company earned nearly $20 billion in revenue from China (9% of its total revenue), but that revenue fell by roughly half year over year in the fiscal first quarter to approximately $4.5 billion. Huang's comment suggests revenue has continued to collapse since the end of the quarter. While the U.S. has approved some licenses for the H200 chip in China, Nvidia has yet to earn any revenue from it and has not included any China data center sales in its forward guidance.
However, Nvidia is never sitting still. Its steady cadence of product releases is one of its competitive strengths. The GPU leader is now a leader in CPUs as well. During the last earnings call in May, management noted that it expects nearly $20 billion in CPU revenue this year. This completely replaces last year's revenue from China.
Today's Change
(
-1.86
%) $
-3.71
Current Price
$
195.29
Nvidia is set for another record year By expanding into the CPU market, Nvidia is entering a space that Intel and Advanced Micro Devices have dominated for decades. AI demand has made the semiconductor competitive landscape more crowded, but Nvidia is differentiating itself by integrating Vera CPUs into a computing system that includes networking, accelerated-computing racks, and GPUs. This kind of innovation is a big reason Nvidia's data center business nearly doubled again in the first quarter, with segment revenue reaching $75 billion.
The Vera Rubin computing platform is designed for advanced reasoning and multiple-step problem-solving to power agentic AI. It features seven purpose-built chips to deliver up to 35x higher inference throughput. It should drive significant revenue when it starts shipping later this year.
Analysts currently expect Nvidia's full-year revenue to increase 81% from last year to $391 billion. That should translate to $8.96 in earnings per share based on the consensus estimate.
Given the uncertainty around government regulations in chip exports, it's unclear when Nvidia will recover its business in China. But for now, the growth opportunity from Vera CPUs is not priced into the stock's valuation, which is 22 times this year's earnings estimate. That looks very cheap relative to Wall Street's earnings growth estimates for the next few years, which currently sit around 45% annualized.
John Ballard has positions in Nvidia. The Motley Fool has positions in and recommends Advanced Micro Devices, Intel, and Nvidia. The Motley Fool has a disclosure policy.
Nvidia (NVDA 1.86%) had a market capitalization of $360 billion at the beginning of 2023, which was right before the artificial intelligence (AI) boom started gathering momentum. The company has since sold millions of its graphics processing units (GPUs) for data centers, which are the primary chips used in AI training and inference workloads, propelling its market cap to $4.8 trillion.
But despite a 13-fold increase in value over the last three years, Nvidia stock is still cheap by one of Wall Street's most widely used valuation metrics. In fact, here's why the stock could more than double from here.
Image source: Nvidia.
Nvidia is about to launch its most powerful chips yet Nvidia's dominance in the market for AI data center chips started in 2022 with its H100 GPU, which was built on its Hopper architecture. The company has since launched Blackwell and Blackwell Ultra GPUs, the latter of which can deliver up to 50 times more performance than the H100 in certain configurations.
Blackwell Ultra GPUs are currently the most sought-after AI chips in the industry, but Nvidia is about to extend its advantage with its new Vera Rubin system, which will ship in the second half of this year. It includes the Rubin GPU, the Vera central processing unit (CPU), and a series of updated networking components. Nvidia says the platform is so powerful that developers can train AI models using 75% fewer GPUs compared to Blackwell.
Vera Rubin can also reduce inference token costs by up to 90% (inference tokens include the text, images, and symbols generated by an AI model in response to a query). In other words, Nvidia's new system will make AI substantially cheaper to use, which could make providers like OpenAI and Anthropic more profitable, driving more demand for chips as a result.
During a conference call with investors on May 20, Nvidia CEO Jensen Huang said every frontier AI company intends to adopt Vera Rubin at launch, which wasn't true for the Blackwell platform. Therefore, he expects it to be far more successful than its predecessor.
Today's Change
(
-1.86
%) $
-3.71
Current Price
$
195.29
Nvidia's revenue and earnings continue to soar Nvidia generated $215.9 billion in total revenue during its fiscal year 2026 (ended Jan. 26), which was up 65% from the prior year. Its data center business accounted for $193.7 billion of that revenue, and it grew by 68%.
Both of those growth rates accelerated in the first quarter of fiscal 2027 (ended April 26). The company generated $81.6 billion in total revenue and $75.2 billion in data center revenue, which represented year-over-year increases of 85% and 92%, respectively, highlighting the sheer momentum in AI-related hardware sales.
Since demand currently exceeds supply for GPUs, Nvidia is able to dictate prices, which is significantly boosting its profit margins. As a result, Wall Street expects the company's generally accepted accounting principles (GAAP) earnings to soar by 91% to $9.36 per share during fiscal 2027 (according to Yahoo! Finance), which could have very positive implications for its stock price.
The price-to-earnings (P/E) ratio is one of the most widely used valuation metrics on Wall Street. If a stock has a P/E ratio of 10, investors are effectively paying $10 for every $1 of the company's earnings. Faster-growing companies tend to attract higher P/E ratios; investors are willing to pay more for their earnings because those companies will, in theory, earn their money back more quickly.
That's why the Nasdaq-100 index, which is full of high-growth technology companies, trades at a P/E ratio of 34.4, whereas the more diversified S&P 500 trades at a P/E ratio of 25.2.
Nvidia's P/E ratio recently fell to 30.09, which was the lowest level since 2019. Moreover, it was a substantial discount to its average P/E of 71.2 over that seven-year period.
NVDA PE Ratio data by YCharts
In other words, Nvidia stock would have to more than double just to trade in line with its long-term average P/E ratio. I'm not suggesting that will happen immediately, but based on the company's projected earnings for fiscal 2027 (which I highlighted earlier), its stock trades at a forward P/E ratio of just 21.5. That means even if its stock doubles over the next six or seven months, its P/E would rise to just 43, which would still be far below its long-term average.
No matter which way you slice it, Nvidia stock looks extremely cheap right now, especially ahead of what could be the biggest product launch in its history. As a result, it could be a great buy right now.
For Immediate ReleaseChicago, IL – June 26, 2026 – Today, Zacks Equity Research 3M Company (MMM - Free Report) , Griffon Corp. (GFF - Free Report) , GPGI, Inc. (GPGI - Free Report) and Public Policy Holding Company, Inc. (PPHC - Free Report)
The Zacks Diversified Operations industry is benefiting from solid momentum in the manufacturing sector and strength across the aerospace and defense industries. Growth in commercial aviation and steady demand in the home and building product markets are key catalysts for the industry’s growth.
However, supply-chain issues have been weighing on the performance of some industry players. 3M Company, Griffon Corp., GPGI, Inc. and Public Policy Holding Company, Inc. are a few industry participants that are likely to capitalize on the opportunities.
About the IndustryThe Zacks Diversified Operations industry includes companies that operate in various end markets, including oil & gas, industrial, electronics, power, aviation, technology, finance, healthcare, chemical, non-residential construction and transportation. Such companies manufacture and provide equipment and solutions, including bioprocessing products, molecular testing-related products, gas and steam turbines, generators, commercial jet engines and engineered fluid-process equipment.
Industry players also provide related services to a large customer base. A few companies offer services in the agriculture, marine and telecommunications markets and are engaged in providing environmental and safety solutions. The diversified market operators have a vast global presence, with exposure in the United States, Japan, India, China, Canada and other countries.
Major Trends Shaping the Future of the Diversified Operations IndustryStrength in the Manufacturing Sector:The industry has been benefiting from an increase in manufacturing activities. After witnessing a contraction in economic activities for 10 successive months till December 2025, the manufacturing sector expanded for the fifth consecutive month in May. Per the Institute for Supply Management’s (ISM) report, the Manufacturing Purchasing Manager’s Index touched 54% in May. A figure more than 50% indicates an expansion in manufacturing activity. Also, the New Orders Index expanded, registering 56.8% in the same month.
Robust Aerospace and Defense Markets:The prospects of multi-sector companies primarily depend on the operating conditions of several end markets. Some factors that currently favor the industry are healthy demand from the aerospace, defense and governmental sectors and infrastructure development. Industry players with exposure to the commercial aviation markets are poised to gain from healthy growth in air transport flight hours. Also, solid demand for several products and equipment in the consumer and professional, and home and building product markets bodes well for some industry participants.
Investments in Innovation & Technological Advancements:The industry participants’ constant focus on innovation, product upgrades and the development of new products to stay competitive in the market should drive growth. With the gradual development of business models and cutting-edge technologies, several industry players have been banking on digitizing their business operations for a while now. Digitization enables industry participants to boost their competitiveness through enhanced operational productivity, product quality and better cost management.
Supply-Chain Disruptions:Supply-chain disruptions, especially related to the availability of electrical and electronic components, have been concerning for the industry participants of late. The latest ISM report’s Supplier Deliveries Index reflects slower deliveries for the seventh straight month in June. Supply-chain issues, if not controlled, might hinder the growth of diversified operation companies, going forward.
Zacks Industry Rank Suggests Strong ProspectsThe Zacks Diversified Operations industry, housed within the broader Zacks Conglomerates sector, currently carries a Zacks Industry Rank #100. This rank places it in the top 40% of 247 Zacks industries.
The group’s Zacks Industry Rank, which is basically the average of the Zacks Rank of all the member stocks, indicates robust prospects. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than two to one.
Given the bullish near-term prospects of the industry, we will present a few stocks that you may want to consider for your portfolio. However, it is worth taking a look at the industry’s shareholder returns and current valuation first.
Industry Lags the S&P 500In the past year, the Zacks Diversified Operations industry has underperformed the S&P 500 composite. The industry has declined 5.8% against the S&P 500 Index’s 23.3% rise.
Industry's Current ValuationOn the basis of forward P/E (F12M), which is a commonly used multiple for valuing diversified operations stocks, the industry is currently trading at 15.49X compared with the S&P 500’s 21.02X.
Over the past five years, the industry has traded as high as 17.56X and as low as 10.38X, with a median of 14.26X.
4 Diversified Operations Stocks Leading the PackGPGI: Based in Saint Somerset, NJ, GPGI provides metal payment cards, secure authentication solutions and engineered injection molding equipment and aftermarket services for the food, packaging, medical and consumer products markets worldwide. The company is benefiting from its diversified portfolio, with market-leading business CompoSecure driving growth. Solid momentum in the Husky business also bodes well.
Though shares of this Zacks Rank #1 (Strong Buy) company have lost 0.6% in the past year, they rose 13% in the past month. Its earnings surpassed the Zacks Consensus Estimate in each of the trailing two quarters, the average surprise being 25.6%. You can see the complete list of today’s Zacks #1 Rank stocks here.
3M: Based in St. Paul, MN, 3M operates as a diversified technology firm. It has manufacturing operations across the globe and serves a diversified customer base throughout the world. The company stands to gain from strong momentum in the Safety and Industrial segment, driven by strength in personal safety, industrial adhesives and tapes, abrasives and electrical markets. Solid momentum in the semiconductor, data center, aerospace and defense, commercial branding and automotive markets is aiding its Transportation and Electronics segment.
Shares of this Zacks Rank #2 (Buy) company have soared 10.1% in the past year. Its earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 4.6%.
Griffon:Based in New York, Griffon engages in the manufacture and sale of a broad range of consumer, professional, home and building products, including garage doors, shutters, home organization products and outdoor living products. GFF is benefiting from resilient repair and remodeling demand across its Clopay operations. Increase in demand for rolling steel door and grille products in commercial construction markets also remains supportive.
The Zacks Rank #2 company’s shares surged 31.9% in the past year. GFF has delivered better-than-expected results in three of the trailing four quarters while missing the mark in one, the average surprise being 3.3%.
Public Policy Holding: Situated in Washington, Public Policy Holding is engaged in providing government relations, public affairs, corporate communications and compliance consulting services to its clients. PPHC is gaining from strength in its Government Relations Consulting segment, driven by stable pricing of retainer contracts both at the U.S. Federal and State levels. Solid momentum in the Corporate Communications & Public Affairs Consulting segment has also been proving beneficial.
This Zacks Rank #2 company’s 2026 earnings estimate remained steady in the past 60 days. The company delivered better-than-expected results in each of the trailing two quarters, the average surprise being 2.1%.
Why Haven't You Looked at Zacks' Top Stocks?Since 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year.
Today you can access their live picks without cost or obligation.
See Stocks Free >>
Join us on Facebook: https://www.facebook.com/ZacksInvestmentResearch/
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
